



(51) International Patent Classification:

A01N 1/02 (2006.01) C12N 5/06 (2006.01)
A61K 35/12 (2015.01)

(21) International Application Number:

PCT/US2016/026597

(22) International Filing Date:

8 April 2016 (08.04.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/146,039 10 April 2015 (10.04.2015) US

(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).

(72) Inventors: TARRAND, Jeffrey; 4706 Braesvalley Dr., Houston, TX 77096 (US). ANDERSSON, Borje; 2632 Carolina Way, Houston, TX 77005 (US).

(74) Agent: FINDLAY, Geoffrey, S.; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR PROLONGED CELL STORAGE

Optical density at 690 nm.




FIG. 3

(57) Abstract: Provided in some aspects are methods and compositions for preserving platelets or other cells. In some embodiments, a platelet storage media or cell storage media may comprise a low molecular weight polyethylene glycol (e.g., PEG-400) to allow for extended storage and/or refrigeration of the platelets or cells.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

DESCRIPTION

COMPOSITIONS AND METHODS FOR PROLONGED CELL STORAGE

BACKGROUND OF THE INVENTION

This application claims the benefit of United States Provisional Patent Application No. 62/146,039, filed April 10, 2015, the entirety of which is incorporated herein by reference.

1. Field of the Invention

[0001] The present invention relates generally to the field of molecular biology and medicine. More particularly, it concerns methods and compositions for prolonged storage of platelets and other cell types.

2. Description of Related Art

[0002] Stored or donated blood platelets are very important for a variety of medical interventions including, *e.g.*, management of a variety of bleeding disorders by use of a platelet transfusion procedure. For example, patients receiving chemotherapy require reliable platelets transfusion support to prevent hemorrhagic death.

[0003] Platelets normally survive for 4 to 5 days on average in the circulation *in vivo*, and approximately 150 billion new platelets are produced per day in normal individuals. (Holm S., 1998). Platelet dynamics can be summarized as follows. Adhesion: platelets stick on a foreign surface. Activation: platelets interact with the surface and react to chemical signals. Aggregation: chemical signals result in the release of von Willebrand factor, platelets change shape, and attach or stick to each other to form a clot. Recruitment: activated platelets recruit more platelets and thrombin to the clot. Retraction and wound repair: platelets mediate a physical shrinkage of the clot which further limits bleeding and brings damaged vessel edges in close contact facilitating local remodeling and repair. These properties of platelets are discussed further in Yip *et al.*, 2005.

[0004] Unlike essentially all other transplantable tissues, platelets do not tolerate refrigeration and these actively metabolizing cells rapidly lose function at room temperature, and even more quickly at 4°C (Egidi *et al.*, 2010). Even brief periods of refrigeration can render platelets dysfunctional, resulting in their rapid clearance from the circulation (Egidi *et al.*, 2010). The mechanism underlying the irreversible cold intolerance of platelets is poorly understood. It has been noted that platelets rapidly change shape at refrigeration temperatures.

(Tablin *et al.*, 1996; Zucker *et al.*, 1954), It has also been recognized that cholesterol levels can impact platelet function, (Insel *et al.* 1978), and more recently that cold storage was sufficient to activate the GPI platelet receptor (Barkalo and Hartwig, 1995).

[0005] The resulting need to keep platelets at room temperature prior to transfusion has imposed a unique set of costly and complex logistical requirements for platelet storage. Because platelets are actively metabolic at room temperature, they require constant agitation in plastic containers permeable to oxygen and that allow release of evolved CO₂ to prevent the toxic consequences of metabolic acidosis. Prolonged room temperature storage conditions typically result in macromolecular degradation and eventual loss of hemostatic functions of platelets, a set of defects known as "the storage lesion". (Thon *et al.*, 2008; Chernoff *et al.*, 1992). This loss of platelet function is a significant problem in platelet management. Further problems can result from the negative feedback mechanism of platelets on platelet production. Even dysfunctional platelets still possess the active enzyme that metabolizes thrombopoietin, thus stored platelet products may both lack platelet function and still inhibit patient marrow megakaryocytes from producing new platelets. (Sungaran *et al.*, 2000).

[0006] Current limitations in the duration for storage of the blood platelets can result in increased blood banking expenses and significant platelet shortages. A large part of the reason for this is that, under current conditions of storage, platelets lose function rapidly. Current regulatory practices typically allow the use of platelets for only up to 5 days following collection. Testing the donated platelets to confirm the absence of bacterial or certain viral contamination problems may require up to a full day. Although there is an urgent medical need for platelets, it is estimated that 30% must be discarded due to their limited functional 'life span' under current storage conditions. (Devine *et al.*, 2010). Random donor platelets typically must be used within 5 days, and similarly apheresis units expire 24hr after processing (Hogman *et al.*, 1992). Clearly, there is a need for improved compositions and methods for storing platelets.

SUMMARY OF THE INVENTION


[0008] The present invention overcomes limitations in the prior art by providing, in various aspects, improved methods and compositions relating to platelet storage media and methods for promoting prolonged storage and retention of platelet function. The platelet storage media may include a polyethylene glycol (PEG), *e.g.*, about 0.1-5.5% of a lower molecular weight PEG (*e.g.*, about 100-500 g/mol). In some embodiments, it is anticipated that one or more of the following cryoprotectants (*e.g.*, having a molecular weight of about 200-1000, or 200-500 g/mol) may be used in combination with, or may be substituted for, the PEG in the media to promote prolonged platelet storage and/or retention of platelet function: glycerol propoxylate (*e.g.*, $M_n \sim 266$), trimethylolpropane ethoxylate (*e.g.*, $M_n \sim 450$), pentaerythritol propoxylate, (*e.g.*, $M_n \sim 426$), or pentaerythritol ethoxylate, (*e.g.*, $M_n \sim 270$). Also provided are methods and compositions relating to improved platelet storage media. In various embodiments, the stored platelets may be administered to a mammalian subject such as a humans to mediate hemostasis or provide a therapeutic benefit. In some embodiments, the platelet storage media may be used to improve storage of other cell types (*e.g.*, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, induced pluripotent stem cells) under refrigerated (*e.g.*, about -5 °C) or freezing (*e.g.*, -70 °C) conditions.

[0009] As shown in the below examples, with standard conditions of rotation/mixing, platelet function was observed to be preserved for 26 days at 5°C and 13 days under room temperature (about ~22-24°C) without detectable loss of hemostatic function in the mouse using platelet storage media comprising particular compositions of a lower molecular weight PEG (*e.g.*, PEG-400). These results provide a significant improvement over currently used storage conditions, where platelets are derived from donor blood but must be discarded after 5 days of room temperature storage (Devine *et al.*, 2010). Thus, in contrast to the current thirty percent of platelets that are discarded due to age of the donated platelets, the longer lifespan of platelets preserved with PEG in various embodiments of the present invention may be used to reduce or eliminate the current wastage of donated platelets. The reduced metabolism observed in cells at refrigeration temperatures should improve or facilitate transport of platelet units and assist with logistics of platelet supply. Cold storage (*e.g.*, storage at 0-10 °C) may be able to provide a significant advantage by reducing microbial growth. Currently, a costly and time consuming process is used to monitor all transfused platelets for microbial contamination. It

is envisioned that inclusion of a PEG in platelet storage media in combination with cold storage conditions may be used to reduce or eliminate the need for contamination screening. It is also envisioned that improved preserved platelet function that can be achieved using PEG containing storage conditions and methods as described herein may allow for reduced amounts of total platelets to be transfused to a patient in order to achieve a desired therapeutic response or therapeutic platelet increment. In some embodiments, stored platelets may be used to treat thrombocytopenia.

[0010] An aspect of the present invention relates to a method for preserving cells, comprising: (a) admixing cells (*e.g.*, platelets) with a cell media comprising a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v); and (b1) wherein if the cells are platelets, then the method comprises storing the cell media comprising the platelets at a temperature of from about 0.1 °C to about 25°C (*e.g.*, from about 0.1 to about 15 °C, from about 20°C to about 25°C); (b2) wherein if the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent stem cells, then the method comprises storing the cell media comprising the platelets at a temperature of from about -157°C to about 15 °C; wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments, the method may involve admixing platelets with a cell media comprising a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v), wherein the method comprises storing the cell media comprising the platelets at a temperature of from about 20°C to about 25°C. In some embodiments, by further including a cryoprotectant (*e.g.*, glycerol (*e.g.*, 3-12%), DMSO (*e.g.*, 0.5-7%), or a poly-(PEG/PPEG) derivative such as pentaerythritol ethoxylate) in the cell media, the cells may be stored at colder temperatures (*e.g.*, about -5°C to about 0.1°C, or -5, -4, -3, -2, -1, 0, 0.1°C, or any range derivable therein). In some embodiments, the concentration of the polyethylene glycol is from about 1% to about 5%, from about 1.1% to about 2.5%, or 0.1, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, or 5.6%, or any range derivable therein. In some embodiments, the cells are platelets, and wherein the method allows for storage of the platelets for more than 5 days without irreversible aggregation of the platelets. In some embodiments, the method allows for storage of the platelets for at least 5-30 days

without irreversible aggregation. The temperature may be from about 0.1-10 °C, or from about 0.1-5°C. In some embodiments, the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells; and wherein the temperature is from about -70 °C to about 0°C. In some embodiments, the polyethylene glycol has an average molecular weight of less than 500 g/mol, or less than 420 g/mol. The polyethylene glycol may be PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450, PEG-475, or PEG-500. In some embodiments, the polyethylene glycol is PEG-400. In some embodiments, the cell media does not contain or only contains trace amounts of ethyleneglycol, diethylene glycol, and/or triethylene glycol. In some embodiments, the cell media comprises or consists of ACD solution, the polyethylene glycol, and the platelets. In some embodiments, the media further comprises about 0.3-3% of a compound having the structure:




wherein: R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a -(CH₂)_x-R₅; wherein: x is 0, 1, 2, or 3; and R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units. In some embodiments, the compound is glycerol propoxylate (*e.g.*, M_n ~266), trimethylolpropane ethoxylate (*e.g.*, M_n ~450), pentaerythritol propoxylate, (*e.g.*, M_n ~426), or pentaerythritol ethoxylate, (*e.g.*, M_n ~270). In some embodiments, the compound is pentaerythritol propoxylate. The cell media may be comprised in an oxygen permeable polymer or plastic bag or container (*e.g.*, comprising or consisting of an oxygen permeable plastic material such as, *e.g.*, di-(2-ethylhexyl) phthalate (DEHOP)). In some embodiments, if the cells are platelets, then the method comprises storing the cell media comprising the platelets at a temperature of from about 0.1 °C to about 15 °C. In some embodiments, the cells are platelets, and wherein the method comprises storing the cell media comprising the platelets at a temperature of from about 20 °C to about 25 °C. In some embodiments, the temperature is about -5, -4, -3, -2, -1, 0, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 °C, or any range derivable therein. The method may further comprise storing the cell media under intermittent or constant rotation. In some embodiments, the cell

media comprises or consists of Acid Citrate Dextrose (ACD), Citrate Phosphate Dextrose (CPD) or a similar storage buffer solution, the polyethylene glycol, and the platelets. The media may comprise ACD or a platelet additive solution. In some embodiments, the cell media further comprises DMSO or β -cyclodextrin. In some embodiments, the cell media does not
5 comprise DMSO or β -cyclodextrin. The cell media may comprise a phosphate buffered saline (PBS) / ACD mixture, or a PBS / ACD / CPD or other commercial buffer mixture (*e.g.*, as described in Table 1 and/or Table 2). In some embodiments, the cells are platelets. In some
10 embodiments, the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments, the media does not contain or only contains trace amounts of ethylene glycol, diethylene glycol, and/or triethylene glycol. In some embodiments, the media may further comprise an additional low molecular weight cryoprotectant such as, *e.g.*, methoxyPEG, glycerol, glycerol propoxylate, trimethylpropane ethoxylate, pentaerythritol ethoxylate, pentaerythritol propoxylate or
15 mixtures of these agents.

[0011] Another aspect of the present invention relates to a cell media for preserving platelets, comprising: (a) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 500 g/mol in a concentration of from about 0.1% to less than 5.6%; (b) ACD, a mixture of phosphate buffered saline (PBS) / ACD, or a mixture of PBS / ACD / CPD
20 or a similar buffer; and (c) viable platelets; wherein the viable platelets (*e.g.*, freshly prepared or isolated) have not undergone irreversible aggregation. In some embodiments, the polyethylene glycol has an average molecular weight of less than 450 g/mol (*e.g.*, less than 420 g/mol). The polyethylene glycol may be PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450, PEG-475, or PEG-500. In
25 some embodiments, the media may comprise a polyethylene glycol such as PEG-550, PEG-600, PEG-650, PEG-700, PEG-750, PEG-800, PEG-850, PEG-900, PEG-950, or PEG-1000. In some embodiments, the polyethylene glycol is PEG-400. In some embodiments, the cell media further comprises DMSO or β -cyclodextrin. In some embodiments, the cell media further comprises DMSO, β -cyclodextrin, methoxyPEG, glycerol, glycerol propoxylate, trimethylpropane ethoxylate, pentaerythritol ethoxylate, pentaerythritol propoxylate or a
30 mixtures of one or more of these agents. In some embodiments, the cell media does not comprise DMSO or β -cyclodextrin, or the cell media only contains trace amounts of DMSO or β -cyclodextrin. In some embodiments, the cell media does not comprise an additional

cryoprotectant, or the cell media only contains trace amounts of an additional cryoprotectant. In some embodiments, the platelets retain substantially normal hemostatic activity when transplanted in a mammal. The media may further comprises of a compound (*e.g.*, at a concentration of about 0.3-3%) having the structure:



5


wherein: R_1 , R_2 , and R_3 are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R_4 is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein: x is 0, 1, 2, or 3; and R_5 is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units. In some embodiments, the compound is glycerol propoxylate (*e.g.*, $M_n \sim 266$), trimethylolpropane ethoxylate (*e.g.*, $M_n \sim 450$), pentaerythritol propoxylate, (*e.g.*, $M_n \sim 426$), or pentaerythritol ethoxylate, (*e.g.*, $M_n \sim 270$).

10

[0012] Yet another aspect of the present invention relates to a cell media for preserving cells, comprising: (a) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 500 g/mol in a concentration of from about 0.1% to less than 5.6%; and (c) viable cells, wherein the viable cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments, the polyethylene glycol has an average molecular weight of less than 420 g/mol. The polyethylene glycol may be PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450, PEG-475, or PEG 500. In some embodiments, the polyethylene glycol is PEG-500, PEG-550, PEG-600, PEG-650, PEG-700, PEG-750, PEG-800, PEG-850, PEG-900, PEG-950, or PEG-1000 may be used. In some embodiments, the polyethylene glycol is PEG-400. The media may further comprises of a compound (*e.g.*, at a concentration of about 0.3-3%) having the structure:

20

25




wherein: R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein: x is 0, 1, 2, or 3; and R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units. In some embodiments, the compound is glycerol propoxylate (*e.g.*, M_n ~266), trimethylolpropane ethoxylate (*e.g.*, M_n ~450), pentaerythritol propoxylate, (*e.g.*, M_n ~426), or pentaerythritol ethoxylate, (*e.g.*, M_n ~270). In some embodiments, the cell media further comprises DMSO or β -cyclodextrin. In some embodiments, the cell media further comprises DMSO, β -cyclodextrin, methoxyPEG, glycerol, glycerol propoxylate, trimethylolpropane ethoxylate, pentaerythritol ethoxylate, pentaerythritol propoxylate, or mixtures of 1, 2, 3, 4, 5, or more of these agents. In some embodiments, the cell media does not comprise DMSO or β -cyclodextrin, or only contains trace amounts of DMSO or β -cyclodextrin, or other cryoprotectants.

[0013] Another aspect of the present invention relates to a bag comprising a cell media of the present invention. The bag may be further defined as a platelet bag or a platelet collection device (*e.g.*, a supplemental storage media additive bag allowing storage media to be added slowly to the bag or collection device). Blood banks typically use interconnected multiple bag blood collection units sold as a complete assembly that includes a needle, and the storage solution in the primary bag. Storage solutions as described herein may be included in a single (primary) bag, in multiple bags, in a specific bag for platelets, in a small pouch, or in a diverter pouch. For example, in some embodiments, a gradual addition of the a cell media as described herein may be added to a platelet bag over a time period of from about 30 seconds to about 5 minutes.

[0014] Yet another aspect of the present invention relates to a method of providing platelets to a mammalian subject comprising administering a therapeutically sufficient amount of a cell media of the present invention. In some embodiments, the subject is a human, and wherein the cell media is further defined as a pharmaceutically acceptable cell media. In some embodiments, the pharmaceutically acceptable cell media is formulated for intravenous administration. In some embodiments, the pharmaceutically acceptable cell media may be formulated for topical or parenteral administration.


[0015] Another aspect of the present invention relates to a method for preserving cells, comprising: (a) admixing platelets with a cell media comprising a poly-(PEG/PPEG) derivative

having an average molecular weight of from 200 g/mol to less than 1000 g/mol (*e.g.*, in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v)), wherein the poly-(PEG/PPEG) derivative has the structure:




5 wherein: R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a -(CH₂)_x-R₅; wherein: x is 0, 1, 2, or 3; and R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units; and (b1) wherein if the cells are platelets, then the method comprises storing
10 the cell media comprising the platelets at a temperature of from about minus 5 °C to about 25 °C; (b2) wherein if the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells, then the method comprises storing the cell media comprising the platelets at a temperature of from about -157°C to about 15 °C; wherein
15 the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments, the poly-(PEG/PPEG) derivative is glycerol propoxylate (M_n ~266), trimethylolpropane ethoxylate (M_n ~450), pentaerythritol propoxylate (M_n ~426), or pentaerythritol ethoxylate, (M_n ~270). The
20 method may comprise storing the cell media comprising the platelets at a temperature of from about 0.1-15°C. In some embodiments, the temperature is about -5, -4, -3, -2, -1, 0, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 °C, or any range derivable therein. The method may comprise intermittently or continuously rotating the cells. In some embodiments, the concentration of the poly-(PEG/PPEG) is from about 1% to about 5%,
25 from about 1.1% to about 2.5%, or 0.1, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, or 5.6%, or any range derivable therein.

[0016] Yet another aspect of the present invention relates to a cell media for preserving platelets, comprising: (a) a poly-(PEG/PPEG) derivative having an average molecular weight of from 200 g/mol to less than 1000 g/mol (*e.g.*, in a concentration of from about 0.1% to less
30 than 5.6%); wherein the poly-(PEG/PPEG) derivative has the structure:



wherein: R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein: x is 0, 1, 2, or 3; and R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units; (b) ACD or a mixture of phosphate buffered saline (PBS) / ACD; and (c) viable platelets; wherein the viable platelets have not undergone irreversible aggregation. In some embodiments, the poly-(PEG/PPEG) derivative is glycerol propoxylate (M_n ~266), trimethylolpropane ethoxylate (M_n ~450), pentaerythritol propoxylate (M_n ~426), or pentaerythritol ethoxylate, (M_n ~270).

[0017] Another aspect of the present invention relates to a cell media for preserving cells, comprising: (a) a poly-(PEG/PPEG) derivative having an average molecular weight of from 200 g/mol to less than 1000 g/mol (*e.g.*, in a concentration of from about 0.1% to less than 5.6%); wherein the poly-(PEG/PPEG) derivative has the structure:



wherein: R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein: x is 0, 1, 2, or 3; and R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units; and (c) viable cells, wherein the viable cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments, the poly-(PEG/PPEG) derivative is glycerol propoxylate (M_n ~266), trimethylolpropane ethoxylate (M_n ~450), pentaerythritol propoxylatepropoxylate (M_n ~426), pentaerythritol ethoxylateethoxylate (M_n ~270), or methoxy-PEG.

[0018] Yet another aspect of the present invention relates to a bag comprising the cell media of the present invention or as described above. In some embodiments, the bag is further

defined as a platelet bag or a platelet collection device (*e.g.*, an oxygen-permeable bag or collection device).

[0019] Another aspect of the present invention relates to a method of providing platelets to a mammalian subject (*e.g.*, a human) comprising administering a therapeutically sufficient amount of a cell media of the present invention or as described above.

[0020] Yet another aspect of the present invention relates to a method for preserving cells, comprising: (a) admixing platelets with a cell media comprising: (i) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v); and (ii) a cryoprotectant; (b) wherein the method comprises storing the cell media comprising the platelets at a temperature of from about -0.5 °C to about 0 °C; wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent. In some embodiments, the cryoprotectant is glycerol, DMSO, or a poly-(PEG/PPEG) derivative. In some embodiments, the cryoprotectant is glycerol. The cell media may comprise about 3-12% glycerol. The cryoprotectant may be DMSO. The cell media may comprise about 0.5-7% DMSO. In some embodiments, the cryoprotectant is the poly-(PEG/PPEG) derivative, wherein the poly-(PEG/PPEG) derivative is pentaerythritol ethoxylate. The cell media may comprise about 0.3-3% pentaerythritol ethoxylate.

[0021] In some embodiments, the platelet storage solution may comprise 1, 2, 3, 4, 5, 6, 7, 8, or more component(s) included in a platelet additive solution as described in Table 1 or Table 2 below. In some embodiments, a platelet storage solution comprises all of the components in one of the platelet additive solution shown in Table 1 or Table 2.

Table 1. Approximate formulation of Platelet Additive Solutions (mM)

Chemical	PAS-Ip	PAS-II (T-sol)	PAS-III (intersol)	PAS111M ssp	PAS G	Msol
NaCl	90	116	77	69	90	110
NaAcetate	27	30	30	30	27	15
NaCitrate	-	10	10	10	11	10
KCl	5	-	-	5	5	5
MgCl ₂	3	-	-	1.5	1.5	3
Posphate	-	-	26	26	-	4
NaGluconate	23	-	-	-	23	-
Glucose	-	-	-	-	-	30

NaHCO ₃	-	-	-	-	-	12
--------------------	---	---	---	---	---	----

Table 2. Platelet Additive Solutions - Anticoagulant-Preservative Solutions***Anticoagulant-Preservative (g/L)**

	Trisodium Citrate	Citric Acid	NaPO ₄	Dextrose	Adenine	Shelf Life
Anticoagulant citrate-dextrose A (ACD-A)†	22.0	8.0	0	24.5	0	21 days
Citrate-phosphate dextrose (CPD)	26.3	3.27	2.22	25.5	0	21 days
Citrate-phosphate-dextrose-dextrose (CP2D)	26.3	3.27	2.22	51.1	0	21 days
Citrate-phosphate-dextrose-adenine (CPDA-1)	26.3	3.27	2.22	31.9	0.275	35 days

*63 mL/450 mL collection, 70 mL/500 mL collection

5 †ACD is used for apheresis components.

[0022] As used herein, a “platelet storage media” refers to a media as described herein that can be used to store platelets or other cell types under refrigerated or freezing conditions. For example, in some embodiments, the platelet storage media may be used to store platelets under refrigerated or freezing conditions. In some embodiments, the platelet storage media may be used to store other cell types such as, *e.g.*, stem cells, apheresis derived hematopoietic cells, sperm cells (*e.g.*, bovine sperm cells), hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells. In some embodiments the other cells are stored in a platelet storage media without the presence of platelets in the storage media. In some preferred embodiments, the platelet storage media comprises a PEG (*e.g.*, about 1-3% PEG-400).

[0023] The stored platelets may be administered to a mammalian subject (*e.g.*, a human patient) to treat a variety of diseases. For example, stored platelets may be administered to a patient to treat, *e.g.*, thrombocytopenia, or platelets may be as a source of platelet derived growth factor to assist wound repair. In some embodiments, platelets or hematopoietic stem

cells may be stored in a platelet storage media as described herein at freezing temperatures (*e.g.*, from about 0 to about -70 °C), and these approaches may be useful for the collection and/or storage of apheresis derived hematopoietic stem cells.

5 [0024] The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the platelets and that is a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, for example, a buffer that stabilizes the platelet preparation to between a pH of from about 6.5 (*e.g.*, Acid
10 Citrate Dextrose) to about 7.4 or about 7.4, the physiological pH of blood, is an example of a pharmaceutically acceptable composition suitable for use with the present invention. In some embodiments, the pharmaceutically acceptable composition is contained in an oxygen permeable plastic bag material (*e.g.*, di-(2-ethylhexyl) phthalate (DEHOP)).

15 [0025] As used herein the specification, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the words "a" or "an" may mean one or more than one.

[0026] The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." As used herein
20 "another" may mean at least a second or more.

[0027] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

25 [0028] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0030] **FIG. 1:** Results showing control platelets at 5°C for 26 days as compared to platelets stored with the addition of PEG-400 at 2% final concentration at 5°C for 26 days. Control results are shown on the left side, and platelets stored with PEG-400 are shown on the right side of **FIG. 1A** and **FIG. 1B**.

[0031] **FIGS. 2A-B:** **FIG. 2A**, PBS (Control) plus 10% hydrogen peroxide showing extensive aggregation. **FIG. 2B**, PBS-2%-PEG400 (Test) plus 10% hydrogen peroxide – showing less aggregation than PBS 10% H₂O₂ control.

[0032] **FIG. 3:** Responsiveness of control (PBS storage) and test (2% PEG-400 storage) platelets to 0 or 10 µg epinephrine challenge.

[0033] **FIGS. 4A-B:** **FIG. 4A**, degranulation of von Willebrand factor (vWF) was observed in the control chilled platelets. **FIG. 4B**, Inclusion of 1.5% PEG-400 in storage media prevented vWF degranulation at 5°C.

[0034] **FIGS. 5A-B:** **FIG. 5A**, Control: strongly fluorescent platelets attached to the larger U937 cell. **FIG. 5B** and **FIG. 5C**, PEG test solution: U937 membranes were observed to be smooth and showed only a few attached strongly fluorescent platelets.

[0035] **FIGS. 6A-C:** **FIG. 6A**, C = PBS control image. Control PBS platelets showed cholesterol capping. **FIG. 6B**, P2 = PBS+2%-PEG400 image. Test platelets stored in 2% PEG-400 overnight showed less cholesterol capping. **FIG. 6C**, P4= PBS plus 4% PEG-400. Test platelets stored in 4% PEG-400 overnight showed less cholesterol capping.

[0036] **FIG. 7:** Change in blotter weight (grams). Results for A= 0 PEG control vs. C= 1% PEG-400 (P = 0.021) are shown. Low grams of blood documents less bleeding.

[0037] **FIG. 8:** Change in blotter weight (grams). Are shown for the 13 day experiment. PEG control data is shown on the left and the 1% PEG400 data is shown on the right.

5 [0038] **FIG. 9:** Combined data from day 11 and day 13. The addition of 1% PEG-400 (“C”) showed significantly more clotting as compared to the control storage solution (“A”). ($P = 0.02$).

[0039] **FIG. 10:** Results for Control platelets and No platelet intervention are shown ($P = 0.0002$).

10 [0040] **FIG. 11:** Results for Room temperature control and test platelets again at 11 days are shown.

[0041] **FIG. 12:** Combined 11 – 13 day Room Temperature results.

[0042] **FIG. 13:** Data for Control 5°C standard vs. 5°C 2% PEG-400 platelets at 19 days are shown ($P = 0.014$).

15 [0043] **FIG. 14:** A Box plot of 5°C control platelets vs. 5°C, 2% PEG-400 platelets 26 days is shown.

[0044] **FIGS. 15A-B:** Platelets stored in media containing 6% glycerol (**FIG. 15A**) and a matched control of platelets stored in a media without glycerol (**FIG. 15B**) are shown.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0045] The present invention, in various aspects, provides methods and compositions for preserving platelet function after collection. For example and as shown in the below examples, it has been found that relatively low concentrations of lower molecular weight PEG may be included in a platelet storage media to allow for extended storage of the platelets. In contrast to these findings, it was found that inclusion of either (1) higher molecular weight PEG in a platelet storage media, or (2) inclusion of higher concentrations of a PEG in a platelet storage media were not able to replicate the beneficial effects of including a lower concentration of a lower molecular weight PEG in the platelet storage media, and irreversible aggregation of platelets was observed, rendering the platelets unsuited for therapeutic administration. Without wishing to be bound by any theory, these results are consistent with the idea that lower molecular weight PEG may interact with platelet membranes and inhibit irreversible aggregation of platelets during storage.

I. Platelet Storage Compositions and Methods

[0046] Platelets are small anucleate cells that are needed for normal coagulation function. Platelets, also called thrombocytes, are produced by megakaryocytes in the bone marrow. Platelets are generally about 2 – 3 um diameter and are membrane bound, anucleate cells found in the bloodstream. They help protect injured mammals from hemorrhagic blood loss by adhering to sites of blood vessel injury and by the formation of a platelet-fibrin clot. Patients with low numbers of platelets in the bloodstream may hemorrhage spontaneously, typically bleeding into the gut, lungs, or brain. These events can be life threatening.

[0047] Platelets may be purified from donor blood via several approaches. For example, platelet concentrates (PCs) may be made from individually donated whole blood units, and pools of several donors (*e.g.*, 5 to 6 “random” donors) may be transfused to provide a useful increment or improvement of platelet support or function for a patient. Alternatively, platelets may be collected from donors using an apheresis procedure. The apheresis procedure typically involves aseptic separation of platelets, where the non-platelet blood cells and plasma are returned to the donor. The donated platelets may be tested to confirm the absence of bacterial or certain viral contamination problems. Regardless of the initial method of preparation, the storage time is normally limited; however, improvements in the storage of

platelets can be achieved in various embodiments using the platelet storage compositions and methods, as described herein.

[0048] In some instances, platelets may be stored in a storage media, *e.g.*, under constant agitation on a flat-bed rotator (*e.g.*, about 20-90, 20, 30, 40, 50, 60, or 70 cycles per minute, or any range derivable therein, or 20-200 cycles per minute; using, *e.g.*, with a 1 inch stroke radius), at about 20–24 °C (68–75.2 °F) or about 20-25°C, in oxygen permeable plastic bags composed of di-(2-ethylhexyl) phthalate (DEHOP). In some embodiments, platelets may be refrigerated, *e.g.*, at about 1-15 °C, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 degrees C, or any range derivable therein. In some embodiments, constant agitation may be useful for extending storage of platelets; nonetheless, it is anticipated that repeated or occasional agitation or no agitation may be used in some embodiments for the storage of platelets as described herein.

[0049] In some embodiments, recombinant thrombopoietin may be administered to a patient in combination with platelets stored using methods of compositions as described herein. Thrombopoietin is a glycoprotein hormone produced by the liver and kidney which can regulate the production of platelets (Kaushansky 2006).

[0050] In some embodiments, human stem cells may be differentiated into platelet producers *in vitro* and stored using compositions and methods as described herein. For example, platelets may be produced from human stem cells using the methods as described in Fujimoto *et al.*, 2003 (Fujimoto *et al.*, 2003).

[0051] Additional methods for the production or storage of platelets that may be used in combination with aspects of the present invention include, *e.g.*, those described in U.S. 2012/0107791 or U.S. 8,052,667, which are incorporated by reference in their entirety without disclaimer. For example, in some embodiments, N-acetylneuraminic acid (sialic acid), or certain nucleotide-sugar molecules, such as CMP-sialic acid or UDP-galactose may optionally be included in a platelet storage media.

[0052] In some embodiments, the platelet storage media may optionally contain one or more of citrate, acetate, calcium, L-carnitine, oxaloacetate, and/ or aspartate, *e.g.*, as described in US 20090191537. In some embodiments, the platelet storage media may optionally contain one or more of buffered Ringers-citrate solution, low glucose, glutamine and or oxaloacetate, malate, fumarate, oxalosuccinate, isocitrate, cis-aconitate, *e.g.*, as described in

WO1985002116. In some embodiments, a calcium chelator with an actin inhibitor may be included in a platelet storage media (*e.g.*, as described in U.S. 5,358,844).

[0053] In some embodiments, platelets are stored in the storage media under room temperature or refrigerated (*e.g.*, 1-10 °C, or about 5 °C) and then directly administered or warmed to room temperature prior to administration to a subject. Thus, in some embodiments, the platelet storage media is a pharmacologically acceptable solution or composition that does not require the removal of components from the platelet storage media or further removal or purification of platelets from the platelet storage media. The ability to directly administer platelets in a storage media (*e.g.*, comprising a low molecular weight PEG such as a pharmaceutically acceptable low molecular weight PEG exhibiting little or no toxicity) can allow, *e.g.*, efficient application or administration of platelets with minimal modification of typical blood banking practices.

[0054] In some embodiments, the platelet storage media comprises saline, phosphate buffered saline (PBS), or Anticoagulant Citrate Dextrose as a base solution (*e.g.*, ACD, ACD-A, CPD, or similar platelet additive solution) in combination with a low molecular weight PEG. For example, the low molecular weight PEG may be PEG-400 in ACD-A.

[0055] Additional components that may be included in a platelet storage media as described herein include DMSO. The DMSO may be present at a concentration of about 0.1 to 5%, 1-3%, 0.1-3%, 1-5%, or 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5%, or any range derivable therein.

[0056] In some embodiments, the platelet storage media may contain cholesterol. For example, cholesterol may be added to a platelet storage media to achieve a level of about 100-200mg/dL range (*e.g.*, in a platelet storage bag or unit of platelets). The amount of cholesterol may range, *e.g.*, from about 25, 50, 75, 100, 125, 150, 175, 200, 225, or 250 mg/dL, or any range derivable therein. In some embodiments, the platelet storage media may contain low cholesterol or diluted plasma or one or more agents that can adsorb cholesterol. In some embodiments, the platelet storage media may provide a low cholesterol, low glucose containing modified ACD buffer with the addition of about 0.5-3% of a low molecular weight PEG.

[0057] In some embodiments, the platelet storage media may comprise or consist of a sterile Polyethylene glycol (*e.g.*, PEG-400 or a molecular weight 400 PEG) in Adenosine, Citrate Dextrose solution. For example if a final concentration of 2% PEG-400 is desired then

the standard 10x ACD solution [Trisodium Citrate 22.0 g/L, Citric Acid 8.0 g/L, Dextrose 24.5 g/L] can be formulated to contain 20% PEG-400. When 9 volumes of fresh platelet / plasma concentrate is added to this 1 volume in the platelet bag, the result will be 2% PEG 400 in 1x standard ACD solution. In some embodiments, the PEG ACD solution is added slowly to the platelets following plasma reduction. In other embodiments, the molecular weight and percent PEG in the composition can vary within a range. In some embodiments, DMSO (*e.g.*, about 1 – 7% DMSO) can be included to facilitate cell freezing.

A. Polyethylene Glycol (PEG)


[0058] PEG is the polymeric form of ethylene glycol. PEG has the formula:



wherein the repeating unit, *n*, is an integer. In some aspects, the nomenclature used to describe PEG includes the average molecular weight of the polymer (*e.g.* PEG-400; PEG-500, PEG-600, etc.). As would be obvious to a person of skill in the art, the average molecular weight does not mean that any particular PEG molecule within the composition has the noted molecular weight but rather that the composition as a whole has the average molecular weight corresponding to that value. In some embodiments, the PEG molecule can have one or both of the terminal hydrogen atom can be replaced with another group including but not limited to an alkyl group (*e.g.* a methyl group or an ethyl group), or a reactive moiety used to attach the PEG to another compound. For example, a PEG-400 composition generally comprises PEG molecules with 8 and 9 repeating units as shown in the formula above, but may also comprises individual PEG molecules with less than 8 or more than 9 repeating units. As the value in the name of the PEG composition represents the average molecular weight, the overall polymer average molecular weight may be modified to obtain an average molecular weight from less than 200 to over a 1000 g/mol (*e.g.* from 2 repeating units to about 22 repeating units, more preferably from 4 repeating units to about 22 repeating units). In some aspects, the PEG is selected with an average molecular weight of about 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, or 600 g/mol, or any range derivable therein. In some embodiments, the PEG has an average molecular weight equal to or less than PEG-1000 (*e.g.*, PEG-400). In some embodiments, a platelet storage media contains or comprises about 1-3% of PEG-400, about 1-3% PEG-300, about 1-3% PEG-350, about 1-3% PEG-500, or about 1-3% PEGs consisting of a mixture of PEG molecules having a molecular weight (mwt) between 300 and 500. In some embodiments, the concentration of the polyethylene glycol is from about

1% to about 5%, from about 1.1% to about 2.5%, or 0.1, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, or 5.6%, or any range derivable therein.

[0059] In some embodiments, a methoxy-PEG or Poly-(methoxy-PEG/PEG) derivative may have the advantage of increased stability. Further, one or more poly-(PEG/PEG) or poly-(PEG/PPG) derivatives (*e.g.*, having a molecular weight of from about 200-700, or 200-600 g/mol) may be used to promote survival of platelets in storage, *e.g.*, during refrigerated or freezing conditions. The poly-(PEG/PPG) derivative preferably has the structure:



wherein:

10 R_1 , R_2 , and R_3 are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

R_4 is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein:

x is 0, 1, 2, or 3; and

15 R_5 is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units;

[0060] For example, it is anticipated that one or more of the following compounds (*e.g.*, having a molecular weight of M_n of about 100-700, or about 200-600 g/mol) could be used in combination with, or substituted for, the PEG in the media to promote prolonged platelet storage and/or retention of platelet function: glycerol propoxylate (*e.g.*, $M_n \sim 266$), trimethylolpropane ethoxylate (*e.g.*, $M_n \sim 450$), pentaerythritol propoxylate, (*e.g.*, $M_n \sim 426$), or pentaerythritol ethoxylate, (*e.g.*, $M_n \sim 270$). In some embodiments, the concentration of the poly(PEG/PPEG) is from about 1% to about 5%, from about 1.1% to about 2.5%, or 0.1, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, or 5.6%, or any range derivable therein.

25 [0061] As used herein, the phrase "low molecular weight PEG" or "lower molecular weight PEG" are used interchangeably and refer to a PEG having an average molecular weight

of from about 200 to about 1000 g/mol, more preferably from about 200 to about 600 g/mol, or from about 300 to about 500 g/mol. In some embodiments, the low molecular weight PEG may have from 2-22, 3-20, 4-15, 4-12, 5-11, 6-10, 7, 8, or 9 repeating units. In some embodiments, the low molecular weight PEG may have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 repeating units, or any range derivable therein.

[0062] Effective amounts of a PEG (*e.g.*, PEG-400) may range from about 0.1 % to about 7% of the platelet storage medium, and more preferably about 1% to 3% of PEG may be included in the platelet storage medium. Effective molecular weights of PEG that may be included in a platelet storage medium may range from 150 to 1000 molecular weight, more preferably 300 to 500 molecular weight, average molecular weight, or nominal molecular weight. The storage conditions may further include one or more of: ACD or similar basal anticoagulant solution, constant agitation, maintenance at room temperature or refrigerated conditions, and/or di-(2-ethylhexyl) phthalate plastic bag, in combination with a storage media containing a lower molecular weight PEG (*e.g.*, PEG-400). PEG-400 is a well-known and generally nontoxic molecule, and it may elute out of platelets to give a blood level ~ 0.025% per unit transfused. In some embodiments, the lower molecular weight PEG may be cleared by the kidneys of subjects after administration of platelets in a platelet storage media comprising the lower molecular weight PEG.

[0063] In some embodiments, inclusion of PEG in platelet storage compositions may result in little or no detectable toxicity when the platelets and storage media are administered to a patient after storage. PEG has been used as a GRAS agent in the food industry, and it has been included in some injectable drug compositions. PEG-400 appears to have relatively low toxicity, and a toxic endpoint ~ 8g/Kg or 0.8% for the whole animal was suggested by studies involving dogs (Li *et al.*, 2011.), and similar levels are tolerated by primates (*e.g.*, 0.4% of body weight for 11 weeks). (Lockard, 1979). It is anticipated that relatively low levels of PEG that might result in a patient after giving a unit of platelets where PEG is included in the storage media (*e.g.*, 0.025% immediately after transfusion) may be well tolerated and result in little or no toxicity in the patient. Without wishing to be bound by any theory, inclusion of a lower molecular weight PEG in a platelet storage media as described herein may promote stabilization of membrane structure of platelets and/or inhibit cold induced aggregation of cholesterol-raft associated transmembrane complexes. Without wishing to be bound by any theory, the data obtained is consistent with the idea that, in contrast to larger molecular weight

PEG, lower molecular weight PEG may be able to penetrate into the membranes of platelets to alter membrane or cell function which may, *e.g.*, prevent or slow the gradual activation that is observed with prolonged room temperature storage and/or prevent or slow the abrupt activation observed under refrigeration conditions.

B. Refrigeration of Platelets in a Platelet Storage Media

[0064] In some embodiments, platelets stored in a platelet storage media (*e.g.*, comprising about 1-5% of a lower molecular weight PEG) may be refrigerated. Refrigeration may comprise maintaining platelets at a temperature of about 0.1-15, 0.1-10, 0.1-8, 1-5, 3-6, 4-5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 degrees C, or any range therein. In some preferred embodiments, platelets in a platelet storage media may be maintained at about 1-15, 2-7, 3-6, or 5°C. In some embodiments, rotation or movement of the platelets may be carried out, *e.g.*, by maintaining the platelets in the platelet storage media in a platelet bag on a rotator. In some embodiments, the movement or rotation of the platelets is substantially continuous. Nonetheless, it is anticipated that sporadic movement or rotation of platelets may be used in some embodiments, and in some embodiments platelets may be maintained in a platelet storage media for a period of time (*e.g.*, during transport of the platelets) without precluding the clinical and therapeutic use of the platelets.

[0065] Refrigeration of platelets is different as compared to freezing platelets below freezing temperatures (*e.g.*, below 0 °C). In some embodiments, it may be possible to maintain the platelets in a platelet storage media as described herein at a temperature near or below 0 °C (*e.g.*, preferably without freezing) for some period of time without precluding clinical use of the platelets, *e.g.*, by including a PEG in the cell storage media as described herein alone or, optionally, in combination with one or more cryoprotectants (*e.g.*, glycerol). Nonetheless, in some preferred embodiments, the platelets are maintained at room temperature or refrigerated conditions, as mentioned above.

[0066] As noted in the below examples, PEG containing storage compositions resulted in significantly improved platelet functional survival at 11- 14 days under room temperature storage conditions on a flat-bed rotator. Further, platelet functionality was successfully preserved under 5°C storage conditions with rotation over 26 days. Data with animal studies indicate that it may be possible to maintain platelets under 5°C storage without the use of continuous rotation. Not requiring rotation may facilitate the transport of platelets between treatment facilities. Without wishing to be bound by any theory, the data obtained supports the

idea that inclusion of particular amounts of a lower molecular weight PEG (*e.g.*, from about 1-5% PEG) may inhibit premature activation in current storage conditions. These platelet storage media can allow for storage of platelets at 5°C, and maintaining the platelets under these refrigerated conditions can lower the metabolism of the platelets and facilitate transport of the platelets over a longer period of time. Storage of platelets under refrigerated conditions (*e.g.*, about 1-10°C or about 5°C) may also inhibit bacterial contamination, which has been a problem with donated platelets (Yomtovian *et al.*, 1993). It is envisioned that 5 °C storage may, in some embodiments, reduce or obviate the need for bacterial contamination screening. In some embodiments, the combination of one or more of these improvements may significantly reduce the complex logistics currently needed for platelet storage and handling.

IV. Examples

[0067] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Materials and Methods

[0068] **Platelet source.** Platelet samples were from the Transfusion Medication service at MDACC. All samples were de-identified residual or discarded donor material less than 3 days old.

[0069] **Microscopy.** Photomicrographs were taken with a Nikon E400 microscope with an Insight 18.2 Color Camera and Spot 5.1 image capture software. No image adjustments were performed. Fluorescent microscopy was performed using a Leica DMIL photomicroscope and Leica LAS V3.8 image acquisition software. No post photographic image adjustments were made.

[0070] Platelet aggregation using epinephrine. Ten ml of 24hr old platelet residual was derived from one platelet unit and split into two 5 ml aliquots in 50 ml tubes. One sample received 10% phosphate buffered saline (PBS) and one 10% PBS containing PEG400 such that the final PEG concentration was 2%. These samples were placed on a flat-bed rotator with a 1 inch stroke, at 70 cycles per min, at 5 °C for 7 days. 100 ul of these platelet suspensions were added to wells of a 96 well U bottom plate. Epinephrine 0.1mg/ml (Pharmaceutical NDC 0409-4921-34-44-048-DK) was diluted with PBS and 100ul was added to test wells to give a final concentration of 10 mcg/ml. The plate was rotated overnight to allow aggregation. The extent of aggregation was read using an ELISA plate reader (Molecular Devices, Vmax) at 690nm wavelength. Platelets, with and without PEG, were also aggregated by the addition of 10% H₂O₂. Hydrogen peroxide is not an agonist for the platelet receptor; however exposure to hydrogen peroxide mimics the platelet storage lesion though membrane ageing. In this study, the inventors tested 2 day old residual platelets from one donor unit by splitting the material in to a 24 well cluster plate. Control platelets had 10% PBS added and were compared to test compositions with the addition of 10% volume PBS plus 2% PEG-400. 10% v/v (Hydrogen peroxide 3%) was then added to all wells simultaneously using a multichannel pipette. Wells were photographed following 1 hr room temperature incubation (see FIGS. 2A-B and FIG. 3). Table 3 presents additional cryoprotective agents scored for the effect on microscopic degranulation (20x high contrast lighting as above).

[0071]

Agent*	Mwt	Days at 5°C	6%	3%	1.5%	0.75%	0.38%	Control^
Glycerol propoxylate	266	6	NT	none	fair	fair	none	none
Trimethylpropane ethoxylate	450	6	NT	none	none	none	none	none
Pentaerythritol ethoxylate	270	6	NT	none	none	none	none	none
Pentaerythritol Propoxylate	426	6	NT	none	none	none	fair	none
Methoxy PEG	350	6	NT	good	good	none	none	none
Glycerol	92	10	good	fair	NT	NT	NT	none

*Final concentrations of cryoprotectants are shown as % solution in ACD-Platelet mixture. NT, Not tested. #, Results - None = no effect detected ~90% complete degranulation, Fair = 25 to 50% of platelets are non-degranulated. Good = >80 are non-degranulated. ^Controls were made in the same manner as test solutions by mixing ACD PBS containing zero cryoprotectant with test platelets in a 1:1 addition. After 10 min rotation at room temp all samples were transferred to 5°C and rotated together.

[0072] Studies of platelet degranulation using anti-von Willebrand factor immunofluorescent staining. Functional, non-degranulated, platelets should retain vWF at high concentrations in their alpha granules. To study the effect of PEG on gradual loss or preservation a direct fluorescent antibody immunofluorescent staining protocol was developed. Slides were air dried for 5 min and immersed in 0.5 % fresh paraformaldehyde in 10% PBS pH 7.3 for 10min. Slides were soaked for 2min in PBS with 5 changes. Subsequently excess PBS was drained and slides immersed for 2 min in ice cold dry acetone. Again, slides were drained and excess acetone was removed with 5 PBS washings of 2 min each. Slides were then immersed in 0.5% filter sterilized BSA in PBS and allowed to block overnight at 4°C. After draining excess block solution, 50ul of primary antibody (Polyclonal rabbit anti-vWF- PB9062, Boster Biological Technology, Pleasanton, CA) at 5ng/ml was applied immediately over the platelet spot and incubated in a humidity chamber for 4 hr at 4°C. Slides were washed with 5 changes of 0.5% BSA/PBS for 5 min each. Excess fluid was again removed and FITC labeled goat anti-rabbit, Sigma F0382, was added 50ug/ml in 0.5% BSA/PBS for 3 hr. Finally, after blotting excess fluid, slides were again washed with 5 changes of 0.5% BSA/PBS, drained, blotted, mounting medium was added, and the slides were cover-slipped. Slides were immediately photographed using a Leica DMIL photomicroscope and Leica LAS V3.8 image acquisition software. No post photographic image adjustments were made.

[0073] Platelet binding to the Macrophage like Cell line U937. U937 is a cell line derived from a patient with Acute Myelo-Monocytic Leukemia. It demonstrates several macrophage-like properties including expression of the Fc receptor. In this binding experiment 5 day old platelets from the blood bank are held in a standard storage media referred to as ACD on a flat-bed shaker under standard conditions of rotation. 'ACD' contains Adenosine, Sodium Citrate, and Dextrose. These platelets were split into two conditions, control and 2% PEG-400, in a 12 well plate format with a final volume of 100ul per well. All wells were incubated overnight at 5 °C. All wells were then stained with fluorescein Diacetate (Sigma product F7378). This agent was protected from light and 1 mg was dissolved in 10ml acetone and stored at -70 °C. FDA was diluted 1:1000 in PBS immediately prior to use (Miyamoto *et al.*, 2000.)

All platelet wells received 2.5 ug final per well of fluorescein diacetate (FA) contained in 50ul PBS. After 1 hr at room temp a further 100ul of PBS was added and the 12 well plates were centrifuged at 3000g for 20min at RT. 150ul excess fluid was carefully removed from all wells and discarded. Platelets were gently suspended. 100ul of washed U937 cells, containing about
 5 1×10^4 per ml, were added to all wells and incubated for 5 min at room temp. The plates were again centrifuged at 500g for 5min at 20 °C. The excess fluid was carefully removed from the wells and the cells were covered with 25ul glycerol based mounting medium and cover-slipped. Wells were examined and photographed with an inverted fluorescence microscope.

[0074] In vitro study of cholesterol membrane mobility using the fluorescent cholesterol probe Filipin. Filipin complex, (F9765 Sigma), was used to demonstrate intra-membrane distribution of cholesterol at 5 °C. (Note 1: Stock solutions were prepared in DMSO that was rigorously dried with an equal volume of A-3 molecular sieve that had been regenerated at 300 °C overnight. The resultant filipin stock 25 mg/ ml DMSO solution was prepared in a nitrogen atmosphere and frozen at -70 °C to limit water induced hydrolysis.)

[0075] Approximately 3ml of residual pooled platelets were obtained after 72hr at standard storage conditions. 100 ul of platelets were mixed with 100 ul of fresh filipin (300ug/ml in PBS + 10% DMSO) in each of 12 wells of a 24 well cluster plate and incubated at room temperature for 35min. (DMSO was included to assist with membrane loading of the highly insoluble filipin molecule.) All wells were then diluted by adding 2.5 ml of PBS and
 20 incubated another 15min to dilute unbound filipin and allow removal of DMSO by dilution. The plate was next centrifuged at 2500g for 20min in a pre-warmed centrifuge at 22 °C. All wells were gently aspirated and the PBS was replaced with 3ml of control or test platelets as follows:

	Control (C)	3ml PBS
25	Test (P2)	3ml of 2% PEG-400 in PBS
	Test (P4)	3ml of 4% PEG-400 in PBS

[0076] All wells were next incubated 20 min at room temperature to allow DMSO to equilibrate. (Note: the final DMSO concentration in the Control wells or the PEG-400 only
 30 wells would be 6 parts in 10,000 or 0.06%.) Next the plate was held at 5 °C overnight and in the morning centrifuged in a 5 °C equilibrated centrifuge at 2,500g for 20 min. Cold 4% Formalin/PBS was carefully added and the plate returned to 5 °C for overnight incubation. At 18hr the plate was allowed to fix again at room temperature in the dark for 4 hours.

Subsequently the formalin was aspirated and the plate washed with 4 changes of 2ml of PBS. Finally, excess fluid was removed and the wells were photographed with an inverted fluorescent microscope. Note 2: Filipin is rapidly photo-bleached with the UV, thus the light intensity was lowered with a barrier filter of ~20% was used. This filter setting was used consistently for all photographs. All photographs were taken under the same camera conditions. No post photographic image alterations were made.

[0077] Studies of platelet storage vs platelet function in a mouse model of thrombocytopenia. Fresh human platelets were obtained from the blood bank. These were pooled, mixed and divided twice to give 4 (new) platelet bags with 65 ml (+/-5ml) in each. Next sterile PBS/ PEG mixtures were made by adding filter sterilized PEG-400 (30% in PBS) serially diluting 1:4. (14ml PBS + 6ml of PEG400 =30% PEG, serially 1:4 diluted with PBS to give 7.5% PEG400, and 1.9% PEG400). Then, 10ml of PBS or PBS/PEG was added into each platelet bag as follows: 10ml PBS is 0 control= A; 10ml of 1.9 is 0.25% peg final in platelets (a low dose tolerated by whole animal see below) =B; 10ml of 7.5% gives 1% PEG-400 final (the max PEG400 dose tolerated by whole animal see below), = C; 10ml of 30% gives 4% about 4 times the max dose tolerated in rhesus monkeys. Units were held at room temp 70 cycles/ min, 1 inch stroke). The platelet units were confirmed to be negative for bacterial growth using 3ml the platelet suspensions in Bactec blood culture bottles at 72 hr.

[0078] CD-1 outbred mice were obtained from Harlan Laboratories. All animals were pretreated with a 0.5 ml IP dose of 185 ug/mouse of filter sterilized fresh acetylsalicylic acid (aspirin) in PBS buffer. Fresh aspirin was used. Salicylate is the active metabolite responsible for most anti-inflammatory and analgesic effects; however, acetylsalicylate is the active moiety for the antiplatelet-aggregation effect and is rapidly hydrolyzed in water. On the following day all mice were given 3 U (heparin equivalents)/animal Lovenox (Enoxaparin Sodium Injection). After a 2 hr period for Lovenox to take full effect, the animals were given 100ul platelets by IV tail vein injection, the platelets were allowed to circulate 20min and the tail vein cut 1 cm from the tip with a new scapula for each animal. Bleeding was measured by collecting drops of blood for exactly 5 min on pre- weighed blotter paper Whatmen-40. The blotters were then weighed and these weights were compared using unpaired t test statistics. Platelets having an excessive amount of RBC in the units were sedimented under gravity in a 50 ml tube for 30 min and only the top 5ml was harvested into a second 50ml tube used for injection.)

EXAMPLE 2*Preservation of Platelet Function*

[0079] Preservation of platelet function was measured using *in vitro* methods and as further described below.

5 [0080] **Experiment A:** Platelets are known to change shape and show partial aggregation when chilled. The goal of the initial experiments was to see if this behavior changed when platelets were incubated in the presence of PEG-400. Two standard random donor platelet concentrates, type O, were mixed by connecting the bags, followed by gravity mixing 8 times. This mixture was equally divided by weight into the two original platelet bags
10 and either 10ml of PBS or 10ml of PEG-400 in PBS was added to the control and test unit respectively. The final concentration of PEG-400 in the unit was 2%. These units were then gently rotated at 70 cycles per minute, with a 1inch stroke length, at 5 °C, over 26 days. At the end of this time aliquots were examined and photographed.

PBS Control**2% PEG-400 in PBS**

15

[0081] Results are shown in FIGS. 1A-B. Control platelets at 5 °C for 26 days can be visually compared to platelets stored with the addition of PEG-400 at 2% final concentration at 5°C for 26 days. As shown in FIGS. 1A-B, the control was observed to be more aggregated and to have more rod shapes than the PEG test platelets. Additional experiments were
20 conducted that showed similar results, and select results are shown in FIGS. 1A-B for illustration purposes.

[0082] **Experiment B:** In a second experiment a state of platelet ‘aging’ was induced using hydrogen peroxide. Hydrogen peroxide is not an agonist for the platelet receptor; however, exposure to hydrogen peroxide predisposes platelets to the “platelet storage lesion”.
25 In this study 2 day old residual platelets derived from one donor unit were tested by splitting the material in to a 24 well cluster plate. Control platelets had 10% PBS added and were compared to test compositions with the addition of 10% volume PBS but containing 2% PEG-400, or 2% PEG-400 plus 1% DMSO. Results are shown in FIGS. 2A-B. The differences in photographic exposure in FIGS. 2A-B are due to heavy precipitation of platelets with resultant
30 clearing of the suspension resulting in less light diffusion in the 10% PBS control medium. As shown in FIGS. 2A-B, for platelets exposed to 10% hydrogen peroxide, the inclusion of 2% PEG400 in the media clearly resulted in less aggregation of the platelets. Images are shown in

FIGS. 2A-B for illustrative purposes, and additional experiments were conducted that showed similar results. The platelets treated with 2% FEG-400 were observed to have less coarse clumping (aggregation), when compared to a matched control derived from the same platelet unit.

5 **[0083] Experiment C:** Without wishing to be bound by any theory, the above observation of reduced aggregation in the presence of PEG suggested two possible hypotheses: one is that PEG may have prevented the effect of cold related aging, and the second is that the PEG may have blocked any agonist induced aggregation. Thus, additional experiments were performed to study epinephrine induced platelet aggregation following cold storage of
10 platelets.

[0084] Fresh donor platelets were supplemented with PBS or PBS 2% PEG-400 as described in the methods, and incubated at 5°C for 7 days. These control and test samples were then loaded side by side on a 96 well plate (ensuring that test and control reading would be made simultaneously). Control wells with zero epinephrine had only PBS added. Test wells
15 had epinephrine in PBS added to give a final concentration of 10ug/well. All loading of PBS or epinephrine agonist used a multichannel pipette to ensure test and control agents were added simultaneously. The plate was rotated in a humidity chamber overnight at room temperature. An ELISA plate reader was used to demonstrate changes in optical density at 690 nm in response to epinephrine challenge.

20 **[0085]** Results are shown in FIG. 3. As shown in FIG. 3, the control platelets failed to show any significant change in OD in response to epinephrine. This was observed based on the fact that cold stored platelets showed significantly higher baseline absorbency in the absence of epinephrine (see FIG. 3, Left hand bar under control platelets). Therefore the control platelets were “preaggregated” in the cold in the absence of any agonist. This is
25 consistent with literature showing aggregation of platelets in the cold. The difference between 0 and 10 µg/ml epinephrine in the control platelets was not significant. Conversely, the PEG 2% stored platelets showed less initial aggregation in the stored state and showed a significant aggregation response to epinephrine.

[0086] Experiment D: von Willebrand Factor (vWF) is a major component of platelet
30 alpha granules. Intact functional platelets should retain these granules. Fresh platelets were divided into 6 aliquots of 4 ml each; 3 controls and 3 test aliquots were prepared by adding

either 10% PBS (v/v) to controls or 10% v/v of 15% PEG400 in PBS to give a final concentration of 1.5 % PEG400 in the test platelet aliquots. All aliquots were incubated at 5°C, +/- 0.1, on a flat bead rotator with a 1 inch stroke at 70 cycles per min for 8 days. At 8 days 3 slides were prepared for both test and control samples using a cytocentrifuge at 2000 g for 2 min. Slides were then stained using anti-von Willebrand Factor DFA protocol in methods. After staining slides were immediately photographed using a Leica DMIL photomicroscope and Leica LAS V3.8 image acquisition software. No post photographic image adjustments were made to images analyzed.

[0087] Results are shown in FIGS. 4A-B. As shown in FIG. 4A, these results show that chilled control platelets show degranulation of vWF. Further, it also demonstrates that 1.5% PEG-400 was sufficient to prevent vWF degranulation at 5°C (more bright green platelets were observed, indicating granules were retained; FIG. 4B).

[0088] **Experiment E:** Chilled platelets are known to be rapidly removed from the circulation by fixed tissue macrophages of the reticuloendothelial system. Thus, an *in vitro* demonstration of platelet adherence to “macrophage-like” cells with or without the addition PEG-400 was performed. The AMMOL U937 cell line is a granulocytic/monocytic leukemia with some macrophage like properties including expression of the Fc receptor. Interestingly, von Willebrand factor of exceptionally high molecular weight (Mwt) is produced by megakaryocytes and is abundant in the Alpha granules of platelets. Reticuloendothelial “fixed” Fc receptors are thought to directly bind to capped (clumped) von Willebrand Factor, resulting in their clearance by fixed macrophages and other Fc receptor sites in the liver, spleen, lung, etc.. (Olsson *et al.*, 2005). In this binding experiment two units of 5 day old type O platelets from the blood bank were held in a standard holding media referred to as ACD on a shaker. ‘ACD’ contains Adenosine, Sodium Citrate, and Dextrose. These were split into two conditions and stained with a high level of fluorescein Diacetate (see Example 1, above, and Miyamoto *et al.*, 2000).

[0089] Control conditions had standard 75ul of ACD suspended platelets, plus 25 µl PBS in the control wells. Test conditions had 75 µl of ACD platelets, plus 25ul of PBS / PEG-400 to give a final PEG-400 concentration of 2% PEG-400 in the test wells. Test and control wells were then held at 5°C overnight on a flat-bed rotator. All wells were stained with a final of 2.5µg Fluoresine diacetate (FDA) per well for 1 hr at room temp. All wells were centrifuged at 3000g for 20 min and excess fluid removed. The platelets were resuspended in 100 µl of

PBS washed U937 cells (approx. 10^4 / ml) and incubated for a further 5 min at room temperature (RT). Cells were then spun at 500 g for 5 min at room temp. The excess fluid was again carefully removed from the wells and the cells covered with 25ul of glycerol based mounting medium. Wells were examined with an inverted fluorescence microscope. Results are shown in FIGS. 5A-C. The experiments were repeated and consistent results were observed as shown in FIGS. 5A-C.

[0090] Result: Control platelets chilled to 5°C overnight were adsorbed to the AMMOL/macrophage like cell line U937. In contrast under the same conditions and with matched platelets but following the addition of 2% PEG-400, only the faint staining of the U937 cells was seen and few heavily stained platelets were seen adherent to the cell surface. The degree of platelet adsorption to the U937 cell line was much less. This confirms a rapid time course for the ‘cold platelet storage lesion’ – in this example overnight storage at 5°C was used. This study also demonstrates a 2% PEG-400 molecular weight (Mwt) composition that can substantially block adsorption of cold stored platelets to macrophage like cells.

[0091] Experiment F: Cholesterol content of platelets has previously been shown to potentiate activation and lower platelet membrane fluidity (Sinha *et al.*, 1977). This applies to platelets with high artificial cholesterol loading, to naturally occurring platelets from patients with hyperlipidemia, (Tomizuka *et al.*, 1990), and to platelets derived from normal donors. (van Lier *et al.*, 2008). The inventor thus wanted to study cholesterol behavior directly in platelet membranes in response to cold storage. The inventor hypothesized that the cold storage injury may be largely related, if not completely related, to physical clumping of high-cholesterol containing domains of the membrane. In the following studies membrane capping of cholesterol was visualized in an *in vitro* experiment, using the fluorescent cholesterol probe filipin. Filipin is a complex mixture of polyterpene compounds that mimic the structure of cholesterol. It is derived from *Streptomyces filipinensis* and is similar to the polyene antibiotic amphotericin B. Filipin is highly fluorescent and binds specifically to cholesterol. It is used as a histochemical stain for cholesterol in the diagnosis of Niemann-Pick disease, and will partition into cholesterol *in vivo* and *in vitro*. It has been used in living cells to study the raft/caveolae endocytosis pathway on mammalian astrocyte cells at concentrations of 3 µg/ml. (Pascual-Lucas *et al.*, 2014).

[0092] Filipin complex (F9765 Sigma) was used to demonstrate intra-membrane distribution of cholesterol at 5°C. [Note 1: Stock solutions were prepared in DMSO that is

rigorously dried with an equal volume of A-3 molecular sieve that had been regenerated at 300°C overnight. The resultant filipin stock 25 mg/ ml DMSO solution was prepared in a nitrogen atmosphere and frozen at -70°C to limit water induced hydrolysis. Note 2: Filipin is rapidly photobleached by UV light, thus light intensity was lowered with a barrier filter ~20%.

5 This filter setting was used consistently for all photographs. All photographs were taken under the same camera conditions. No post photographic image alterations were made.]

[0093] Approximately 3ml of residual pooled platelets were obtained after 72hr at standard storage conditions. 100 µl of platelets were mixed with 100 µl of fresh filipin (300ug/ml in PBS + 10% DMSO) in each of 12 wells of a 24 well cluster plate and incubated
10 at room temperature for 35min. (DMSO was included to assist with membrane loading of the highly insoluble filipin molecule.) All wells were then diluted by adding 2.5 ml of PBS and incubated another 15min to dilute unbound filipin and allow removal of DMSO by dilution. The plate was next centrifuged at 2500g for 20min in a pre-warmed centrifuge at 22°C. All wells were gently aspirated and the PBS was replaced with 3ml of control or test storage
15 solution as follows:

Control (C)	3ml PBS
Test (P2)	3ml of 2% PEG-400 in PBS
Test (P4)	3ml of 4% PEG-400 in PBS

20 [0094] All wells were again incubated 20 min at room temperature to allow DMSO to equilibrate. (Note: the final DMSO concentration in the Control wells or the Peg-400 only wells would be 6 parts in 10,000 or 0.06%.) Next the plate was held at 5°C overnight and in the morning centrifuged in a 5°C equilibrated centrifuge at 2,500g for 20 min. Cold 4% Formalin/PBS was carefully added and the plate returned to 5°C for overnight incubation. At
25 18hr the plate was allowed to fix again at room temperature in the dark for 4 hours. Subsequently the formalin was aspirated and the plate washed with 4 changes of 2ml of PBS. Finally, excess fluid was removed and the wells were photographed with an inverted fluorescent microscope. Results are shown in FIGS. 6A-C.

[0095] **Results:** Controls show accumulation of the cholesterol probe filipin in clusters
30 around the platelets membranes (FIG, 6A). Treatment conditions with 2% PEG-400 (FIG. 6B) show less filipin clustering, as do treatment conditions with 4% PEG (FIG. 6C). Additional images were obtained that were consistent with these results.

[0096] The results of the above *in vitro* experiments replicate previous findings that cold conditions (here 5°C, +/- 0.1) are sufficient to induce platelet aggregation, loss of receptor agonist interaction, adsorption to macrophage like cells, and degranulation as measured by the loss of vWG granules. A surprising finding shown in the results is that the inclusion of a relatively narrow range of low molecular weight PEGs, in a particular range of w/v %, in storage solutions was sufficient to substantially block these 'cold storage lesion' effects. Further, the inventor observed cholesterol capping under cold storage conditions. Without wishing to be bound by any theory, since capping is frequently associated with signal transduction and since the above late effects (aggregation, degranulation) require signal transduction (Zolla *et al.*), the results support the idea that cholesterol capping under cold storage is sufficient to recapitulate all features of the cold storage lesion and that enhancing cholesterol mobility with low molecular weight PEG is sufficient to reverse all features of the cold storage lesion effects.

EXAMPLE 3

Preservation of Platelet Function In Vivo

[0097] Preservation of platelet function was observed *in vivo* using a mouse animal model. The results of the below experiments show that treatment of platelets with a storage media containing PEGs of various molecular weights and final % composition can prolong platelet function as demonstrated in an *in vivo* mouse model.

[0098] Briefly, the animal model experiments were performed as follows. Fresh human platelets were obtained from a blood bank, consisting of 3 ABO 'O' units and 2 ABO 'A' units. These were pooled, mixed and divided twice to give 4 (new) platelet bags with 75 ml (+/-5ml) in each. Next sterile PBS/ PEG mixtures were made by adding filter sterilized PEG-400 (30% in PBS) serially diluting 1:4. (14ml PBS + 6ml of PEG =30% PEG, serial ¼ diluted with PBS to give 7.5% PEG, and 1.9% PEG400.). 10ml of PBS or PBS/PEG was then added to each platelet bag as follows. As shown in FIG. 7, 10ml of PBS is the 0 control= A ; 10ml of 1.9 is 0.25% peg final in platelets (a low dose tolerated by whole animal see below) =B; 10ml of 7.5 gives 1% PEG-400 final (approximately the max PEG400 dose tolerated by whole animal see below), = C; 10ml of 30% PEG400 gives 4% PEG400 final, about 4 times the max dose tolerated in rhesus monkeys. Units were held at room temp 140 cycles/ min, 0.5 inch stroke). The platelet units were confirmed as negative for bacterial growth using 3ml in Bactec blood culture bottles at 72 hr.

[0099] CD-1 outbred mice were obtained from Harlan Laboratories. All animals were pretreated with a 0.5 ml IP dose of 185 µg/mouse of filter sterilized fresh acetylsalicylic acid in PBS buffer. On the following day all mice were given 3 U (heparin equivalents)/animal Lovenox. (Note: Aspirin was fresh. Salicylate is the active metabolite responsible for most anti-inflammatory and analgesic effects; however, acetylsalicylate is the active moiety for the antiplatelet-aggregation effect and is rapidly hydrolyzed in water. After a 2 hr period for Lovenox effect the animals were given 100ul platelets by IV tail vein injection, the platelets were allowed to circulate 30min and the tail vein cut 1 cm from tip with a new scapula for each animal. Bleeding was measured by collecting drops of blood for exactly 5 min on pre-weighed blotter paper Whatmen-40. The blotters were then weighed and these weights were compared using unpaired t test statistics. Platelets containing an excessive amount of RBC in the units were sedimented under gravity in a 50 ml tube for 30 min and only the top 5ml was harvested into a second 50ml tube used for injection.

[00100] **Experiment A:** Platelets were pooled (11 day old platelets) Obtained 4 type 'O' platelet units from the blood bank. Mixed and divided platelets again into 4 equal 95ml aliquots in platelet unit bags. These pooled platelets contained ACD. Supplemental storage agent were added as follows:

A = pbs control

B = pbs + 0.2% PEG-400, final

C = pbs + 1% PEG-400, final

D = pbs + 3% PEG-300, final

placed on a rotator at room temp (24°C).

On day 11 , gave 0.3mg salicylic acid IP

On day 12, gave 0.5 ml 3 units heparin IP

Waited one hr.

And then injected platelets

Waited 15 min for injected platelets

to recover function *In situ* ...

Then snipped tail -- blotted 5 min +-30sec

[00101] **Statistical analysis:** As shown in FIG. 7, a graphic BOX plot is provided showing 50% of values within the box with a median line and 25% in each wing. Any included outliers are shown as a dot with an open circle around it. Any excluded outliers

are shown as large black circles. (John Tukey outlier method. Similar to *mean* and SD describing a distribution, here outliers are defined relative to the *median* as either $3 \times$ Inter-Quartile Range (IQR) or more above the third quartile or $3 \times$ IQR or more below the first quartile.)

5 **[00102]** **Experiment B:** The experiment was repeated at day 13 (13 day old platelets) using the same platelet units and same conditions and using 6 additional animals. Variability was very high due to difficult injections. The experiment did not reach significance due to low numbers and high viability, but shows a trend similar to the first experiment. Results are shown in FIG. 8.

10 **[00103]** For further statistical analysis the day 11 and day 13 data were combined since conditions are closely matched, and the results are shown in FIG. 9. As shown in FIG. 9, the addition of 1% PEG-400, "C", shows significantly more clotting vs the standard platelet storage condition. ($P = 0.02$).

15 **[00104]** **Experiment C:** *Bleeding control* using the same pretreatment conditions and one day old platelets under standard conditions vs *no platelets*. Results are shown in FIG. 10.

Day 1 platelets Result

N 3 controls vs 3 max bleed

Ave 0.007 vs 0.07 blotter weight in grams

20 Sd 0.05 vs 0.05 Standard deviation in grams

[00105] As shown in FIG. 10, this data confirms that at 1 day old platelets stored under standard conditions are functional and that the maximum bleeding as demonstrated by the zero platelet group is consistent with prior studies.

25 **[00106]** **Experiment D:** It was not feasible to evaluate more than two groups of mice during any one experiment. Therefore 0.25% PEG-400 and 4% PEG-400 were not further investigated. In experiment D 1% PEG-400 in PBS was again used as the test condition and again compared to a matched control derived from the same platelet unit, but with only the addition of an equal volume of PBS.

5-11 actual - two apheresis units of 48 hr age were received. They were rotated under standard conditions:

70, 1 inch stroke cycles per min at 22- 25°C. They were Both O and both were rejected by the blood bank due to hepatitis B Core antibody positive status.

5 [00107] Each apheresis recovers a higher number of platelets. One apheresis unit is equivalent to ~7 Random donor platelet concentrates. The material was divided into 6 platelet storage bags using 60ml syringe and 16g needle to transfer 60ml of platelets slowly (1min) into new unit bags. Unit A was used to make room temp control and room temp PEG 1% test units. Unit A was also used to prepare 5 °C control and 5 °C PEG 2% test units.

10 [00108] The room temperature pair was tested again at 11 days to demonstrate reproducibility. The 5°C storage pair was tested at 23 days because it was suspected that they could be functional based on *in vitro* observations.

15 [00109] Results are shown in FIG. 11. Room temperature control and test platelets again at 11 days. As shown in FIG. 11, the experiments showed high variability but the observed trend was similar.

 [00110] Combined 11-13 day room temperature results were combined and are shown in FIG. 12.

20 [00111] Experimental conditions were closely matched so results may be combined to overcome the small number of animals in each group. (N=3) Combined data were from prior experiments day 11, day 13, and day11. All controls and tests were at room temperature (RT) with paired platelet source vs PEG-400 1%, and pretreated with aspirin (-24 hr) and 3 iu Lovenox (-1to 5hr). Following injection, a delay of 15 min was allowed to occur so that platelets could circulate in all animals to allow for recovery of function of platelets. The tail vein was again cut 1cm from the tip and the blood collected for 5min.

25 [00112] Results: Weight of blood after tail vein cut is given in grams for combined 11 day groups.

Table 3

Control (pbs) Room temp.	vs.	PEG (1% PEG-400 in PBS) at Room temp.
.03 control	.04	PEG (5/23/14 group, $P=0.27$)
.18	.04	
.1	.06	
.1	.04	(3/11/14 group, $P = 0.021$)
.14	.05	
.09	.06	
.13	.05	(3/13/14 group, $P = 0.027$)
.06	.03	
.03	.02	

Analysis of combined data:

5

Controls	vs	1% PEG-400
N=9		N=9
$\bar{X}=0.095$		$\bar{X}=0.043$
SD=0.05		SD=0.013
		$P = 0.008$

[00113] **Conclusions:** 1) The difference between control platelets and PEG platelets is reproducible. 2) PEG platelets are active at day 11-13. 3) Profound anticoagulation appears associated with high variability in bleeding in the controls as determined by weight method.

10

[00114] **Experiment E:** Day 19, 5°C control platelets vs 5 °C 2% PEG-400 test platelets. The experimental set up was very similar to previous with minor differences in timing. 0.3ml of 1.8mg/ml aspirin was given at about 1:00 (made fresh 1:10 from -70°C- 18mg/ml stock in PBS) The next day- 0.5 (5 units) Lovenox was given at about 12:30. The experiment was started 2hr later. 30ml of both platelet groups was sedimented for 45 min at 4°C to remove any aggregated clumps. (None were visible.) 4ml from the top was removed as the experimental test and control materials. After injection the platelets were allowed to

15

circulate for 20min. The tail vein was then cut 1cm from the tip and allowed 6 min bleeding with collection of drops on pre-weighed Whatman- 40 blotter paper. (#4 - thick). Results are shown in FIG. 13.

[00115] **Conclusion:** The inclusion of 2% final concentration of PEG-400 Mwt

5 in the standard ACD platelet storage medium allowed **19 days** of storage at 5 °C +/- 0.02°C, with mixing on a flat-bed shaker with a 1 inch stroke diameter and 70 cycles per min continuous shaking.

[00116] **Experiment F:** 5°C Control platelets vs. 5°C 2%, PEG-400, platelets

10 after 26 days of shaking. All animals got 0.3ml of 1.8mg/ml aspirin I.P. on 6/6/14 and 0.5 ml of 10 iu /ml lovenox IP, 2 hr prior to platelet injection on 6/7. 0.1ml of test or control platelets were given by IV tail vein injection and allowed to incubate in the animals for 20 min then the terminal 1 cm of tail vein was cut with a scalpel and blood collected on blotter paper 6 min. (Both control 5°C platelets and peg 5°C platelets were sub-cultured on chocolate agar and no growth was seen at 48 hr.) Results are shown in FIG. 14.

15 [00117] **Conclusions:** Modified platelet storage conditions using 2% final weight of PEG-400 added to the standard ACD platelet storage units and rotated on a flat-bed shaker with at 1 inch diameter stroke and 70 cycles per minute at 5°C successfully preserved platelet function for 26 days. Control platelet, receiving only PBS were dysfunctional.

[00118] **Summary of animal model results:** A thrombocytopenic mouse

20 model was used to assess the functional status of stored platelets. In patients with coagulopathies most hospitals offer a clinical “bleeding time” assay. The bleeding time assay is used to make *an integrated assessment* of all elements required for thrombostasis. In patients with a coagulopathy the patient’s ability to accomplish hemostasis – regardless of the specific coagulopathy or defect- can be measured by the bleeding time. The bleeding time is performed
25 by making six small standardized cuts in the skin of the arm and counting the number of seconds until bleeding stops. Although *in vitro* studies can model some elements of platelet function, many elements – such as thrombin binding and clot retraction - cannot yet be duplicated. Thus, the bleeding time assay is still necessary. In a similar way, while the current
30 *in vitro* studies demonstrate known defects in aged or cold stored platelets (aggregation, macrophage adherence, etc.), they do not confirm that the new storage conditions can be used to provide functional platelets *in vivo*.

[00119] There are three elements that may be important to understanding the above animal model results, as follows: (1) Why aspirin was used, (2) why Heparin was used, and (3) why the mice were incubated for 15 to 30 min prior to bleeding. In the above animal model a simple IP injection of acetylsalicylic acid was given one day prior to the study. The dose can inactivate the cyclooxygenase pathway of mouse platelets. Similar to humans, the cyclooxygenase of circulating mouse platelets is permanently poisoned by aspirin and platelet function is only slowly restored by the production of new platelets. At the dose used, the half-life of aspirin in the blood stream of the mouse has been measured at 30 min to 1h. Thus, 20 to 40 half-lives are available to remove unbound aspirin from the mouse prior to giving human platelets the next day. Thus, mouse platelet function may be eliminated and following injection human platelet function can be demonstrated. Second, a high dose of Lovenox, a synthetic long-lived heparin-like molecule to arrest the classical thrombin / fibrinogen coagulation cascade, was given. This suppression is predicted to peak at 1 to 3 hrs following IP Lovenox, based on the half-life of 5 to 7 hr. Again, when the stored human platelets were administered, they were substantially the only factor remaining to assist coagulation of these mice. Third, the platelets were allowed to circulate for 15 to 30 min in the above experiments. This allowed damaged or aggregated platelets to be removed and PEG to elute from platelets – and this models the anticipated human therapeutic pattern of use. Note: the blood volume of a 30g mouse is ~2ml and thus the 100ul dose represents 5% of murine blood volume. Humans typically receive 4 to 7 units of random donor units at one transfusion corresponding to 5 to 9% of blood volume. In this context, the animal model provides strong evidence of functional thrombocyte transfusion after 26 days of storage in a practical dosing context. Further, refrigeration may avoid the need for bacteriologic assessment, and may facilitate overnight transport of platelets from areas of excess to areas of need.

[00120] The above data demonstrates that ACD storage solution can be supplemented with PEG-400 to give a more effective storage solution. Effective platelet function was shown at room temp out to 13 days at room temperature. Successful platelet storage with retention of function using these compositions was also observed out to 26 days at 5°C. The agents used have a beneficial effect on platelets storage when tested in an animal model, extending platelet storage life to at least 13 days under room temperature storage and 26 days under 5°C storage.

EXAMPLE 4

Compositions and Compounds for Enhanced Storage of Platelets

[00121] In addition to the improvements observed with PEG as demonstrated in the above examples, the inventors observed improved platelet preservation when certain additional compounds were added to the storage solution. As demonstrated below these compounds were included in the media in a particular range of doses, and an enhancement of platelet function was observed.

[00122] The following methods were used: "Fresh" in-date 2 day old blood bank O pos random donor platelets were recovered from segments and held in a 50cc tub with rotation 22°C, 70 cycles /min 1 inch stroke) for 30min. Glycerol (Fisher tissue grade product) was obtained from virology diluted to 50% in sterile saline and filter sterilized. 12g glycerol were added to 12ml sterile saline (BioMeriux – vitek saline) and mixed. This mixture was filter sterilized using a 0.45um filter (CELLULOSE ACETATE). Dilutions were made of the above saline to a concentration 50%, 25%, 12%, 6%, 3%. 200ul of platelets were withdrawn slowly (8 sec) and add slowly to 7 sterile 2ml microcentrifuge tubes. 200 ul of 50%, 25%, 12% 6%, and 3% glycerol/ saline and two controls using 200ul saline, were then added to the platelets with slow mixing. Thus the final glycerol concentrations = 25, 12, 6, 3, and 1.5. These aliquots were allowed to rotate at room temp as above for 5 min and then placed on a rotator at 70 cycles / min with a 1 inch stroke at 5°C (temp previously equilibrated and documented at 5°C.)

[00123] **Results:** At day 3, dark dense platelets were observed, indicating degranulation in the control groups (in both control groups A & B). A variation in platelet size was observed: small and dense indicating degranulation, vs. normal morphology pale plump platelets without the dense small degranulated appearance. Degranulation in response to cold storage is associated with the first step of the platelet activation GP-1 signal resulting in α-granule degranulation and massive extracellular release of vWF. (Suhasini *et al.*, 2010). Table 4 presents a summary of additional cryoprotective agents scored for the effect on microscopic degranulation (20x high contrast lighting as above).

Table 4. Studies of the effect of cryoprotective on platelet degranulation.

Agent*	Mwt	Days at 5°C	6%	3%	1.5%	0.75%	0.38%	Control^
Glycerol propoxylate	266	6	NT	none	fair	fair	none	none
Trimethylpropane ethoxylate	450	6	NT	none	none	none	none	none
Pentaerythritol ethoxylate	270	6	NT	none	none	none	none	none
Pentaerythritol Propoxylate	426	6	NT	none	none	none	fair	none
Methoxy PEG	350	6	NT	good	good	none	none	none
Glycerol	92	10	good	fair	NT	NT	NT	none

*Final concentrations of cryoprotectants are shown as % solution in ACD-Platelet mixture. NT, Not tested. #, Results - None = no effect detected ~90% complete degranulation, Fair = 25 to 50% of platelets are non-degranulated. Good= >80 are non-degranulated. ^Controls were made in the same manner as test solutions by mixing ACD PBS containing zero cryoprotectant with test platelets in a 1:1 addition. After 10 min rotation at room temp all samples were transferred to 5°C and rotated together.

[00124] Results are shown in FIGS. 15A-B.

[00125] When 3% glycerol was included in the media, at day 3, a light color of platelets was observed, indicating granule preservation (in both 3% glycerol groups A & B).

[00126] At day 6, for the control groups, dark dense platelets were observed, indicating degranulation (for both control groups A & B).

[00127] When 3% glycerol was included in the media, at day 6, a light color of platelets was observed, indicating granule preservation (in both 3% glycerol groups A & B).

[00128] At day 10, for the control groups, dark dense platelets were observed, indicating degranulation (for both control groups A & B).

[00129] When 3% glycerol or 6% glycerol was included in the media, at day 10, a light color of platelets was observed, indicating granule preservation (in both the 3% glycerol groups A & B).

[00130] **Conclusion:** 3% and 6% glycerol, in a suitable physiologic aqueous solution, prevented 5°C induced degranulation at 3, 6, and 10 days. These data support the idea that this biologically well tolerated compound may thus be used or included in platelet storage solutions, *e.g.*, at a 1 % to 12 % final concentration. Without wishing to be bound by any theory, these results support the idea that the glycerol may act as a cryoprotectant towards platelets.

[00131] The inventors anticipate that the following compounds may also be used to enhance platelet storage when used at 1% to 40% of their normal cryoprotectant levels (*i.e.*, at 0.1% to 6% final concentration): glycerol propoxylate (mwt 266), trimethylolpropane ethoxylate (mwt 450), pentaerythritol propoxylate (mwt 426), pentaerythritol ethoxylate (mwt 270).

[00132] Further, there is a likelihood that PEG 400 (0.3 to 3%) or PEG 350 (0.3 to 4%) can be advantageously combined with the lower concentration range of the cryoprotectant agents listed below with all possible permutation of the above concentrations, except that even lower levels of glycerol, glycerol propoxylate, trimethylolpropane ethoxylate, pentaerythritol propoxylate, and/or pentaerythritol ethoxylate, could be advantageously used. Without being bound by theory, the inventors anticipate that pentaerythritol propoxylate may be particularly useful at preserving transmembrane proteins, including pore structures with hydrophobic domains during the process of protein crystallization. This property supports the idea that combinations using the demonstrated cholesterol disaggregating / lipid bilayer penetrating properties of low molecular weight PEG with pentaerythritol propoxylate may be used to achieve a synergy of functional stabilization at concentrations well below the typical levels used for cryopreservation and crystallization. The inventors anticipate that the combination of a PEG as described herein synergize with when used in combination with pentaerythritol propoxylate.

* * *

[00133] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the

concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the

5 spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

Patent Publication No. 2009/0191537

Patent Publication No. 2012/0107791

U.S. Patent No. 5,358,844

U.S. Patent No. 8,052,667

WO1985002116

Barkalo K., Hartwig J.H. The role of actin filament barbed-end exposure in cytoskeletal dynamics and cell motility. *Biochem. Soc. Trans.*, 23; 451-456, 1995

Chernoff *et al.*, The cellular and molecular basis of the platelet storage lesion. *Transfusion* V 32(4): 386-390, 1992.

Devine *et al.*, The Platelet Storage Lesion. *Clinics in Laboratory Medicine* 30:475-487, 2010.

Egidi *et al.*, Troubleshooting in platelet storage temperature and new perspectives through proteomics. [review] *Blood Transfusion* 8:(Suppl 3);s73-s8, 2010.

Fujimoto *et al.*, 2003 .

Hogman, C. F., New trends in the preparation and storage of platelets. *Transfusion* 32 (1): 3-6, 1992.

Holm S. Storage and quality assessment of platelets. [review] *Vox Sanguinis* 74:207-216, 1998.

Insel, PA, Nirenberg P, Turnbull J, Shattil SJ. Relationships between Membrane cholesterol, alpha-adrenergic receptors, and platelet function. *Biochemistry* 17(24):5269-73, 1978

Kaushansky K. "Lineage-specific hematopoietic growth factors". *N. Engl. J. Med.* 354 (19): 2034-45, 2006.

Lier *et al.*, Role of membrane cholesterol in platelet calcium signalling in response to VWF and collagen under stasis and flow. *Thromb Haemost*; 99(6):1068-78, 2008.

Lockard JS. *Epilepsia* 20:77-84, 1979.

Miyamoto *et al.*, Establishment of Fluorescein diacetate and ethidium bromide assay for quality assessment of isolated islets. *Cell transplantation* 9:681-86, 2000.

Olsson *et al.*, Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. *Blood*; 105:3577-3582, 2005.

Pascual-Lucas *et al.*, LPS or ethanol triggers claritin rafts/ caveolae- dependent endocytosis of TLR4 in cortical astrocytes. *J Neurochemistry* 2014, 129:448-462.

- Sinha *et al.*, Cyclic AMP Metabolism in Cholesterol-rich Platelets. *Journal of Biological Chemistry* 252;(10):3310-3314, 1977.
- Suhasini K, *et al.* A revised model of platelet aggregation. *J Clin Invest* 105:783, 2010
- 5 Sungaran *et al.*, The role of platelet α -granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. *Blood* 95:3094-3101, 2000.
- Tablin *et al.*, Membrane phase transition of intact human platelets: correlation with cold-induced activation. *J Cell Physiol.* Aug;168(2):305-13, 1996.
- Tetsuro-Takahiro Fujimoto *et al.*, Production of functional platelets by differentiated embryonic stem (ES) cells in vitro. *Blood* 102: 4044-4051, 2003.
- 10 Thon *et al.*, Platelet Storage Lesion: A New Understanding From a Proteomic Perspective. *Transfusion Medicine Reviews*; 22(4): 268-279, 2008.
- Tomizuka *et al.*, Hypersensitivity to thromboxane A₂ in cholesterol-rich human platelets. *Thromb Haemost*; 64(4):594-9, 1990.
- 15 Yip *et al.*, "Primary platelet adhesion receptors". IUBMB Life (*International Union of Biochemistry and Molecular Biology: Life*) 57 (2): 103–8, 2005.
- Yomtovian *et al.*, A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. *Transfusion*; 33:902–909, 1993.
- Zucker *et al.*, Reversible alteration in platelet morphology produced by anticoagulants and by cold. *Blood* 28:524–534, 1954.

CLAIMS**WHAT IS CLAIMED IS:**

- 5 1. A method for preserving cells, comprising:
 - (a) admixing cells with a cell media comprising a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v); and
 - (b1) wherein if the cells are platelets, then the method comprises storing the cell media
 10 comprising the platelets at a temperature of from about 0.1 °C to about 25 °C;
 - (b2) wherein if the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells, then the method comprises storing the cell media comprising the platelets at a temperature of from about -157°C to about 15 °C;
 - 15 wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent stem cells.
2. The method of claim 1, wherein the concentration of the polyethylene glycol is from about 1% to about 5%.
- 20 3. The method of claim 1, wherein the concentration of the polyethylene glycol is from about 1.1% to about 2.5%.
4. The method of any one of claims 1-3, wherein the cells are platelets, and wherein the method allows for storage of the platelets for more than 5 days without irreversible aggregation of the platelets.
- 25 5. The method of claim 4, wherein the method allows for storage of the platelets for at least 5-30 days without irreversible aggregation.
6. The method of any one of claims 1-5, wherein the temperature is from about 0.1-10 °C.
7. The method of claim 6, wherein the temperature is from about 0.1-5°C.
8. The method of any one of claims 1-3, wherein the cells are stem cells, apheresis derived
 30 hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood,

pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells; and wherein the temperature is from about -70 °C to about 0°C.

9. The method of any one of claims 1-7, wherein the polyethylene glycol has an average molecular weight of less than 500 g/mol.

5 10. The method of claim 9, wherein the polyethylene glycol has an average molecular weight of less than 420 g/mol.

11. The method of claim 9, wherein the polyethylene glycol is PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450, PEG-475, or PEG-500.

10 12. The method of claim 11, wherein the polyethylene glycol is PEG-400.

13. The method of any one of claims 1-12, wherein the cell media does not contain or only contains trace amounts of ethyleneglycol, diethylene glycol, and/or triethylene glycol.

14. The method of any one of claims 1-13, wherein the cell media comprises or consists of ACD solution, the polyethylene glycol, and the platelets.

15 15. The method of any one of claims 1-13, wherein the media comprises ACD or a platelet additive solution.

16. The method of any one of claims 1-15, wherein the cell media further comprises DMSO or β -cyclodextrin.

17. The method of any one of claims 1-15, wherein the cell media does not comprise DMSO
20 or β -cyclodextrin.


18. The method of any one of claims 1-17, wherein the cell media comprises a phosphate buffered saline (PBS) / ACD mixture.

19. The method of any one of claims 1-18, wherein the cells are platelets.

20. The method of any one of claims 1-18, wherein the cells are stem cells, apheresis
25 derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells.

21. The method of any one of claims 1-20, wherein the media does not contain or only contains trace amounts of ethylene glycol, diethylene glycol, and/or triethylene glycol.

22. The method of any one of claims 1-21, wherein the media further comprises about 0.3-3% of a compound having the structure:



wherein:

5 R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

 R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein:

 x is 0, 1, 2, or 3; and

10 R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units.

23. The method of claim 22, wherein the compound is glycerol propoxylate (*e.g.*, M_n ~266), trimethylolpropane ethoxylate (*e.g.*, M_n ~450), pentaerythritol propoxylate, (*e.g.*, M_n ~426), or pentaerythritol ethoxylate, (*e.g.*, M_n ~270).

15 24. The method of claim 22, wherein the compound is pentaerythritol propoxylate.

25. The method of any one of claims 1-23, wherein the cell media is comprised in an oxygen permeable polymer or plastic bag or container.

26. The method of any one of claims 1-25, wherein if the cells are platelets, then the method comprises storing the cell media comprising the platelets at a temperature of from about 0.1 °C
20 to about 15 °C.

27. The method of any one of claims 1-25, wherein the cells are platelets, and wherein the method comprises storing the cell media comprising the platelets at a temperature of from about 20 °C to about 25 °C.

28. The method of any one of claims 26-27, wherein the method further comprises storing
25 the cell media under intermittent or constant rotation.

29. A cell media for preserving platelets, comprising:

(a) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 500 g/mol in a concentration of from about 0.1% to less than 5.6%;

(b) ACD or a mixture of phosphate buffered saline (PBS) / ACD; and

(c) viable platelets;

5 wherein the viable platelets have not undergone irreversible aggregation.

30. The cell media of claim 29, wherein the polyethylene glycol has an average molecular weight of less than 420 g/mol.

31. The cell media of claim 29, wherein the polyethylene glycol is PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450,
10 PEG-475, or PEG-500.


32. The cell media of claim 31, wherein the polyethylene glycol is PEG-400.

33. The cell media of any one of claims 29-32, wherein the cell media further comprises DMSO or β -cyclodextrin.

34. The cell media of any one of claims 29-32, wherein the cell media does not comprise
15 DMSO or β -cyclodextrin.

35. The cell media of any one of claims 29-33, wherein the platelets retain substantially normal hemostatic activity when transplanted in a mammal.

36. The cell media of any one of claims 29-35, wherein the media further comprises about 0.3-3% of a compound having the structure:



wherein:

R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

25 R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein:

x is 0, 1, 2, or 3; and

R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units.

37. The cell media of claim 36, wherein the compound is glycerol propoxylate (*e.g.*, M_n ~266), trimethylolpropane ethoxylate (*e.g.*, M_n ~450), pentaerythritol propoxylate, (*e.g.*, M_n ~426), or pentaerythritol ethoxylate, (*e.g.*, M_n ~270).

38. A cell media for preserving cells, comprising:

(a) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 500 g/mol in a concentration of from about 0.1% to less than 5.6%; and


(c) viable cells, wherein the viable cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells.

39. The cell media of claim 38, wherein the polyethylene glycol has an average molecular weight of less than 420 g/mol.

40. The cell media of claim 38, wherein the polyethylene glycol is PEG-200, PEG-225, PEG-250, PEG-275, PEG-300, PEG-325, PEG-350, PEG-375, PEG-400, PEG-425, PEG-450, PEG-475, or PEG-500.

41. The cell media of claim 40, wherein the polyethylene glycol is PEG-400.

42. The cell media of any one of claims 38-41, wherein the media further comprises about 0.3-3% of a compound having the structure:



wherein:

R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a -(CH₂)_x-R₅; wherein:

x is 0, 1, 2, or 3; and

R_5 is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units;

43. The cell media of claim 42, wherein the compound is glycerol propoxylate (*e.g.*, $M_n \sim 266$), trimethylolpropane ethoxylate (*e.g.*, $M_n \sim 450$), pentaerythritol propoxylate, (*e.g.*, $M_n \sim 426$), or pentaerythritol ethoxylate, (*e.g.*, $M_n \sim 270$).

44. The cell media of any one of claims 38-41, wherein the cell media further comprises DMSO or β -cyclodextrin.

45. The cell media of any one of claims 38-41, wherein the cell media does not comprise DMSO or β -cyclodextrin.

46. A bag comprising the cell media of any one of claims 29-45.

47. The bag of claim 46, wherein the bag is further defined as a platelet bag or a platelet collection device.

48. A method of providing platelets to a mammalian subject comprising administering a therapeutically sufficient amount of a cell media of any one of claims 29-45.


49. The method of claim 48, wherein the subject is a human, and wherein the cell media is further defined as a pharmaceutically acceptable cell media.

50. The method of claim 49, wherein the pharmaceutically acceptable cell media is formulated for intravenous administration.

51. A method for preserving cells, comprising:

(a) admixing platelets with a cell media comprising a poly-(PEG/PPEG) derivative having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v),

wherein the poly-(PEG/PPEG) derivative has the structure:



wherein:

R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$, wherein:

5 x is 0, 1, 2, or 3; and

R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units;

and

10 (b1) wherein if the cells are platelets, then the method comprises storing the cell media comprising the platelets at a temperature of from about minus 5 °C to about 25 °C;

(b2) wherein if the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells, then the method comprises storing the cell media comprising the platelets at a temperature of from about -157°C to about 15 °C;

15 wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells.


52. The method of claim 51, wherein the poly-(PEG/PPEG) derivative is glycerol propoxylate (M_n ~266), trimethylolpropane ethoxylate (M_n ~450), pentaerythritol propoxylate
20 (M_n ~426), or pentaerythritol ethoxylate, (M_n ~270).

53. The method of any one of claims 51-52, wherein the method comprises storing the cell media comprising the platelets at a temperature of from about 0.1-15°C.

54. The method of claim 53, wherein the method comprises intermittently or continuously rotating the cells.

25 55. A cell media for preserving platelets, comprising:

(a) a poly-(PEG/PPEG) derivative having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% to less than 5.6%; wherein the poly-(PEG/PPEG) derivative has the structure:



wherein:

R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein:

x is 0, 1, 2, or 3; and

R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units;

(b) ACD or a mixture of phosphate buffered saline (PBS) / ACD; and


(c) viable platelets;

wherein the viable platelets have not undergone irreversible aggregation.

56. The cell media of claim 55, wherein the poly-(PEG/PPEG) derivative is glycerol propoxylate ($M_n \sim 266$), trimethylolpropane ethoxylate ($M_n \sim 450$), pentaerythritol propoxylate ($M_n \sim 426$), or pentaerythritol ethoxylate, ($M_n \sim 270$).

57. A cell media for preserving cells, comprising:

(a) a poly-(PEG/PPEG) derivative having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% to less than 5.6%; wherein the poly-(PEG/PPEG) derivative has the structure:



wherein:

R₁, R₂, and R₃ are each independently hydrogen, a polyethylene glycol comprising 1-5 repeating units, or a polypropylene glycol comprising 1-5 repeating units; and

R₄ is hydrogen, alkyl_(C1-12), substituted alkyl_(C1-12), or a $-(CH_2)_x-R_5$; wherein:

5 x is 0, 1, 2, or 3; and

R₅ is a polyethylene glycol comprising 1-5 repeating units or a polypropylene glycol comprising 1-5 repeating units;

and

(c) viable cells, wherein the viable cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells.

58. The cell media of claim 55, wherein the poly-(PEG/PPEG) derivative is glycerol propoxylate ($M_n \sim 266$), trimethylolpropane ethoxylate ($M_n \sim 450$), pentaerythritol propoxylatepropoxylate ($M_n \sim 426$), pentaerythritol ethoxylateethoxylate ($M_n \sim 270$), or methoxy-PEG.

59. A bag comprising the cell media of any one of claims 55-58.

60. The bag of claim 59, wherein the bag is further defined as a platelet bag or a platelet collection device.

61. A method of providing platelets to a mammalian subject comprising administering a
20 therapeutically sufficient amount of a cell media of any one of claims 55-58.

62. A method for preserving cells, comprising:

(a) admixing platelets with a cell media comprising:


(i) a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6 % (wt/v); and

(ii) a cryoprotectant;


(b) wherein the method comprises storing the cell media comprising the platelets at a temperature of from about -0.5 °C to about 0 °C;

wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent.

63. The method of claim 62, wherein the cryoprotectant is glycerol, DMSO, or a poly-
5 (PEG/PPEG) derivative.
64. The method of claim 63, wherein the cryoprotectant is glycerol.
65. The method of claim 64, wherein the cell media comprises about 3-12% glycerol.
66. The method of claim 63, wherein the cryoprotectant is DMSO.
67. The method of claim 66, wherein the cell media comprises about 0.5-7% DMSO.
- 10 68. The method of claim 63, wherein the cryoprotectant is the poly-(PEG/PPEG) derivative, wherein the poly-(PEG/PPEG) derivative is pentaerythritol ethoxylate.
69. The method of claim 64, wherein the cell media comprises about 0.3-3% pentaerythritol ethoxylate.




/Control




PEG

FIG. 1A



Control



PEG

FIG. 1B




FIG. 2A




FIG. 2B

Optical density at 690 nm.





FIG. 3



Control - 20x photo



1.5% PEG test solution - 20x photo

FIG. 4




FIG. 5A. Control.




FIG. 5B. PEG test solution.




FIG. 5C. PEG test solution.




FIG. 6A.




FIG. 6B.





FIG. 6C



A= 0 PEG control vs. C= 1% PEG-400 ($P = 0.021$)

FIG. 7

Blotter weight - grams




FIG. 8

Combined data from day 11 and day 13


Student's t-Test Results
The results of an unpaired t-test performed at 20:05 on 13-MAR-2014

t = 3.77
sdev = 0.313E-01
degrees of freedom = 18 The probability of this result, assuming the null hypothesis, is 0.000

Group A: Number of Items = 6
3.000E-02 5.000E-02 9.000E-02 0.100 0.150 0.140
Mean = 9.167E-02
95% confidence interval for Mean: 5.3239E-02 thru 0.1201
Standard Deviation = 4.167E-02
Hi = 0.140 Low = 3.000E-02
Median = 9.500E-02
Average Absolute Deviation from Median = 4.167E-02


Group B: Number of Items = 6
2.000E-02 3.000E-02 4.000E-02 5.000E-02 5.000E-02 6.000E-02
Mean = 4.167E-02
95% confidence interval for Mean: 1.3239E-02 thru 7.0094E-02
Standard Deviation = 1.472E-02
Hi = 6.000E-02 Low = 2.000E-02
Median = 4.500E-02
Average Absolute Deviation from Median = 1.167E-02

Data Reference 098E




Condition A vs C combined 11 and 13 day data
A is the control C contains 1% PEG-400

FIG. 9




Control platelets vs No platelet intervention, $P = 0.0002$

FIG. 10




Control platelets vs. 1% PEG-400 ($P = 0.27$, NS)

FIG. 11

Combined 11 – 13 day Room Temperature results:

Control platelets vs. 1% PEG-400 ($P = 0.008$)
Note: includes multiple RT studies at days 11-13


FIG. 12



Control 5°C standard vs. 5°C 2% PEG-400 platelets at 19 days. ($P=0.014$)

FIG. 13

Graphic (Box plot): 5°C control platelets vs. 5°C, 2% PEG-400 platelets 26 days.



5°C Control vs. 5°C 2% PEG -400 (P= 0.016)

FIG. 14

Platelets with glycerol 6% added.



FIG. 15A

Matched control - Platelets without glycerol.



FIG. 15B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/26597

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 1/02; A61K 35/12; C12N 5/06 (2016.01)

CPC - A01N 1/0221, 1/02; A61K 35/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A01N 1/02; A61K 35/12; C12N 5/06 (2016.01)

CPC: A01N 1/0221, 1/02; A61K 35/19

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, Other Countries (INPADOC), RU, AT, CH, TH, BR, PH); EBSCO;
 Google/Google Scholar, IP.com: platelet, cell, stem, media, storage, preserve, PEG, polyethylene, glycol, aggregation, DMSO,
 cyclodextrin, glycerol, pentaerythritol, ethoxylate

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2009/0041737 A1 (MAURER, E et al.) 12 February 2009; abstract; figure 6; paragraphs [0015], [0041], [0058]-[0059], [0066], [0080], [0089]-[0090]	1-3, 4/1-3, 5/4/1-3, 29-32, 33/29-32, 34/29-32, 51, 53/51, 55, 59/55, 60/59/55, 61/55, 62-63, 66 8/1-3, 38-41, 42/38-41, 43/42/38-41, 44/38-41, 45/38-41, 52, 53/52, 54/53/51-52, 56-58, 59/56-58, 60/59/56-58, 61/56-58, 64-65, 67
Y	US 2012/0128641 A1 (AUSTEN, JR., WG) 24 May 2012; paragraphs [0004], [0029]	1, 8/1-3, 38-41, 42/38-41, 43/42/38-41, 44/38-41, 45/38-41, 57-58, 59/57-58, 60/59/57-58, 61/57-58
Y	WO 2012/027138 A1 (ARSENAL MEDICAL, INC.) 01 March 2012; page 29, lines 24-26	43/42/38-41, 52, 53/52, 54/53/52, 56, 59/56, 60/69/56, 61/56
Y	US 5,656,498 A (IIJIMA, T et al.) 12 August 1997; column 7, lines 31-38	54/53/51-52
Y	US 2008/0241244 A1 (TRUONG-LE, V) 02 October 2008; paragraphs [0018], [0077]	64-65
Y	WO 2006/044790 A2 (ZYMEQUEST, INC.) 27 April 2006; page 85, lines 3-8	67

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 May 2016 (23.05.2016)

Date of mailing of the international search report

27 JUN 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/26597

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6-7, 9-28, 35-37, 46-50
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.